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Abstract 
Irreversible Electroporation (IRE) has gained increasing popularity in the cancer 
treatment field during the past decade due to many advantages over other focal 
therapies. Despite early success in pre-clinical and clinical IRE trials, in vivo studies 
have shown that IRE suffers from an inability to destroy large volumes of cancer tissue 
without repeating treatment and/or increasing the applied electrical dose to dangerous 
levels. There are approaches to expand the treatment volume by IRE with the addition of 
chemotherapeutic or cytotoxic agents. While these studies demonstrated improved cell 
killing, the focus was on enhancing the ability of chemotherapeutic drugs or cytotoxic 
agents to enter and kill the cancer cells rather than enhancing the efficacy of IRE itself. 
 
Therefore, the aim of this work is to investigate the ability to increase the destructive 
capability of IRE without relying on cytotoxic drugs. Specifically, mechanisms that 
directly modify membrane properties should reduce the voltage threshold for lethal 
permeabilization and therefore increase the efficacy of cell killing and therefore the 
volume treated after a given IRE level. Two methods to achieve these changes are 
proposed in this study: 1) addition of surfactant (e.g. Dimethyl sulfoxide, or DMSO) to 
directly interact with membrane lipids thereby changing membrane line tension and 
surface tension, and 2) use of pulse timing (i.e. introduction and persistence of defects in 
the membrane between pulses).  
 
Here then we began by Investigation of IRE enhancement in vitro to understand the 
impacts of our proposed mechanisms and their ideal working parameters. We found that 
the best enhancement effect was achieved with addition of 5% v/v DMSO, which 
resulted in a significant increase of 75% more cell destruction compared to baseline IRE. 
v 
Similarly with pulse timing, when dividing the pulses into three trains with 30s delays in 
between, an enhancement of 67% more cell destruction was achieved compared to 
baseline IRE. 
 
Next we tested our IRE enhancement approaches in an in vivo dorsal skin fold chamber 
(DSFC) model of prostate cancer with optimal parameters selected from our in vitro 
experiments. The results reproducibly showed that more than 120% and 101% 
enhancement in the treatment volume were achieved by the addition of DMSO and 
pulse timing, respectively, with two independent injury assessment methods (histological 
and perfusion defect). 
 
Finally, we translated one of the enhancement approaches (pulse timing) to an in vivo 
hind limb model of prostate cancer and demonstrated that more than 33% additional 
tumor destruction and 2 weeks longer tumor growth delay could be achieved compared 
to baseline IRE treatment without relying on any cytotoxic drugs or agents. 
 
Because DMSO is commercially available and regularly used at low concentrations 
(<10% v/v) in clinic, this approach could easily be integrated into current IRE procedures 
to increase the treatment efficacy. In addition, introducing pulse timing delays in IRE also 
increases the destructive potential of IRE without the introduction of any foreign agents 
into the body. Further opportunities exist in improving the adjuvant delivery methods, 
optimizing the pulse timing delivery approach and understanding the fundamental 
mechanisms of IRE. Nevertheless, we suggest that the simple and safe nature of our 
proposed approaches compared with cytotoxic drugs may help to translate IRE into the 
clinic.   
vi 
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Chapter 1. A Review of Basic to Clinical Studies of Irreversible Electroporation Therapy 
 
Contributing Authors: Chunlan Jiang, Rafael Davalos, and John C. Bischof 
 
The following chapter is under review in publication:  
C. Jiang, R. Davalos, and J. C. Bischof, “A Review of Basic to Clinical Studies of 
Irreversible Electroporation Therapy,” IEEE Trans. on Biomed. Eng., 2014.  
 
1.1 Introduction 
Electroporation, also known as electropermeabilization, is a technique that utilizes high 
magnitude electric pulses (1000s of Volts/cm) to induce permeability increase in cell 
membranes. While some of the molecular events that take place at the membrane level 
have not been fully elucidated, there is general agreement in the literature [1], [2] that 
nm-sized metastable structural defects are created when the plasma membrane is 
exposed to the external pulsed electric field. These defects are thought to be the source 
of the increased permeability from electroporation first used for material (i.e. DNA, 
protein, molecule) transfer into cells and then later as a therapeutic modality to treat 
diseases as reviewed below. 
 
The first observation of electroporation was reported in the 1950s on electrically 
stimulated membranes, and was described as “membrane breakdown” [3]. Soon 
thereafter, the non-thermal killing effect of strong electric field pulses was discovered 
and reported by Sale in a study on micro-organisms [4]. Many studies followed into the 
early 1990s demonstrating the utility of electroporation in molecular biology, mainly as a 
method to introduce foreign molecules into living cells. Although further exploration and 
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optimization studies continue, electroporation is now sufficiently mature for commercial 
application for molecular and gene transfer in vitro, as has been reviewed by Jaroszeski 
[5]–[7].  
 
The introduction of electroporation to cancer therapy originated from one of its drug 
delivery applications. Specifically, electroporation was used to assist uptake of chemo 
drug molecules into tumor cells [8]. The pairing of electroporation and chemo drug 
delivery quickly gained popularity and is an independent treatment termed 
electrochemotherapy (ECT). ECT has been translated to clinical practice [9]–[12] with 
reported objective response rates ranging from 72 to 100% [13], [14].  As a result ECT is 
one of the most well-established clinical applications of electroporation today [15]. 
 
In 2005, the concept of using electroporation as a monotherapy (i.e. without cytotoxic 
drugs or in conjunction with thermal effects) to destroy tissue was proposed by Davalos, 
Mir, and Rubinsky [16]. The term “irreversible electroporation (IRE)” was used to 
distinguish between cell destruction rather than reversible permeabilization used in 
previous embodiments of electroporation for molecular biology applications. In this 
study, IRE alone showed the ability to destroy undesirable tissues in the body in a 
manner similar to more traditional focal thermal therapies such as radiofrequency (RF) 
heating or cryosurgery. The advantages over thermal therapy were immediately realized 
due to IRE’s potential to (1) reduce collateral thermal effects (i.e. over-treatment) and (2) 
lack of the influence of local blood perfusion on treatment outcome (i.e. no blood sink or 
source to heat transfer). The new application of IRE as an independent cancer therapy 
and its unique advantages quickly triggered widespread interest from the scientific 
community. Much effort has since been invested to study its efficacy as a cancer 
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therapy, both in vitro [17]–[20] and in vivo [21]–[25]. A wide variety of cell [17]–[20], 
organ [26]–[28], and animal [21], [24], [29] models have been used to characterize the 
destructive potential of IRE for different cancer types. These studies have provided 
valuable experimental results and treatment planning protocols (IRE threshold, pulse 
parameters, etc.) including probe delivery (probe design, placement, intra-operative 
imaging methods, etc.), injury evaluation (methods and timing), and treatment efficacy. 
While reviews of IRE are now beginning to be published [1], [2], [30], [31], [31], [32], a 
systematic summary and categorization of basic to clinical IRE studies allowing ready 
access and comparison between protocols and parameters has not yet been provided 
for researchers and clinicians who are new to the field.  
 
Therefore, the main purpose of this chapter is to give a critical review of the in vitro, 
translational, and clinical work based on major experimental studies on IRE therapy in 
the past decade, and provide organized data and facts to assist further research, 
optimization, and clinical applications with IRE. 
 
1.2 Proposed Mechanisms of IRE 
This topic has been well evaluated in many well-written reviews [32]–[35]. For 
completeness and discussion of later in vitro and in vivo results, a brief overview of 
mechanisms is given here.  
 
Electroporation is essentially a membrane phenomenon that involves behavior of the 
lipid plasma membrane under the intense stimulation of external electric field (1000s 
V/cm). The early observation of “membrane breakdown” in electrically stimulated 
membranes dates back more than half a century ago [3]. However, it was not until the 
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1970s that insights into IRE mechanisms began to accumulate with the development of 
experimental platforms. Using a natural vesicular membrane system, Neumann [36] 
detected  the release of catecholamines induced by intense electric field and confirmed 
the transient change of membrane permeability during electroporation. In a subsequent 
series of studies [37]–[42], it was suggested that the site of interaction between the 
electric field and the cell subjects was the cell membrane. These findings stimulated 
great interest in modeling the membrane lipid system and developing membrane based 
mechanisms for electroporation.  
 
 
Figure 1.1. Illustration of electroporation process and outcome. 
 
The potential distribution surrounding an isolated spherical cell (Figure 1.1) with a non-
conducting membrane in an external electric field      can be described by Laplace 
equation, and has the following solution for the transmembrane voltage (    
 
                   (1.1) 
 
where   is the radius of the cell, and   is the angle between the site on the cell 
membrane where   is measured and the direction of     . The relationship between   
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and      in Eqn (1.1) has been validated by Kinosita’s experiments on electroporation 
with electric field-sensitive fluorescent dyes [43], [44]. Following this approximation, for a 
typical eukaryotic cell with a radius of       , it takes an external field strength of 
667V/cm to achieve a transmembrane voltage of 1V [33]. Note that Eqn (1.1) applies 
only to the scenario when the cell to cell distance is much greater than the radius of a 
single cell (as in dilute cell suspension) and membrane charging time is negligible. More 
comprehensive discussions on electric field-induced transmembrane potential can be 
found in [34], [45]–[47]. When the cell density and charging time are considered, Eqn 
(1.1) needs to be generalized into Eqn (1.2) 
 
 
                    
 
 
   
where         
 
  
 
 
   
   
(1.2) 
 
in which a coefficient   (mV/(V/cm)) is introduced to reflect the influence of cell packing 
density, i.e. the ratio of cell radius to cell separation distance, and the membrane 
charging time constant    determined by    (specific membrane capacitance),    and    
(intracellular and extracellular specific conductivities).  
 
The integrity of the membrane after electroporation is dependent on various parameters, 
but primarily on the transmembrane voltage. In the important case of cell membranes, 
reversible poration is usually found for      [33]. Temporary poration allows ions and 
molecules that are normally impermeable to the cell membrane to pass through, but 
these pathways usually reseal after electroporation and eventually lead to cell survival. 
For transmembrane voltage greater than 1V, and usually with longer pulsing, 
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electroporation may cause permanent membrane destruction (irreversible). Although the 
cell injury can be caused directly or indirectly from the pulsing, the creation of extended 
lethal membrane defects is presently believed to be responsible for cell killing after IRE.  
 
There have been several different types of theoretical models explaining membrane 
stability at elevated transmembrane voltage. In earlier studies, it was suggested that 
membrane rupture is caused by an electromechanical collapse due to the compression 
of the entire membrane [48]. However, according to this model, there is a deterministic 
“breakdown voltage” for each specific cell type, which is contradictory to the stochastic 
nature of IRE from experiments. Based on the earlier studies by Litster [49] and [50] on 
stability of spontaneous pores on membranes, Weaver [51] proposed an energy based 
pore formation model for membrane rupture during electroporation. In this model, the 
free energy for pore formation is dependent on both the membrane properties and the 
applied external electric field 
 
                             (1.3) 
 
where   (   ) is the free energy to create a pore of radius  ,   and   are the edge line 
tension and surface tension of the membrane, respectively, and    represents the 
contrast of dielectric constants of water and lipid. This model accounts for factors of both 
the applied external electric field and the membrane’s intrinsic physical properties, such 
as line tension and surface tension, which could also influence the outcome of 
electroporation [52] (Figure 1.2). Furthermore, it allows for estimation of the pore 
formation rate with calculations described in [33], [53], [54].  
7 
 
 
Figure 1.2. Reported IRE influencing factors: (a) competing factors (surface tension and edge 
line tension) during pore formation, (b) nucleation based energy model and critical pore radius & 
energy with baseline      or decreased edge line tension 
 
The mechanisms whereby cells die post IRE continue to be actively investigated. 
Several mechanisms with experimental support have been proposed and are reviewed 
here. One mechanism is lethal membrane disruption from repetitive electrical pulsing. 
This lethal event is predicted in existing electroporation theories [1], [2], [33], [35], [53] 
considering the creation of aqueous pores. Direct visualization of the transient pore 
formation process has been elusive due to the combination of time scale and spatial 
resolution limit of the imaging methods. However, many attempts based on indirect or 
“fix-then-process” approaches have been made to observe the membrane defect 
induced by electroporation. Using electron microscope, Chang et. al. [55] were able to 
observe numerous “pore-like” structures from rapid frozen electroporation treated 
sample (Figure 1.3a). The observed pore structure sizes ranged from 20 nm to as large 
as 120 nm in diameter. Because direct poration is difficult to detect, researchers have 
often resorted to indirect measurements which may support either poration or 
permeabilization. For instance, sharp changes in electrical conductivity can reflect 
alteration of membrane permeability (Figure 1.3c), and can be used to detect the 
occurrence of electroporation [56]–[59]. Dye uptake and volumetric response of cells 
(a) (b) 
8 
(Figure 1.3b) have also been used to evaluate pore formation during electroporation 
[17]–[19], [60]. In addition, for the non-vital defects that completely reseal after 
electroporation, many secondary events, such as electro-conformational protein 
denaturation [34], osmotic imbalance, flush in/out of ions, depletion of ATP [61], or 
uptake of toxic/foreign molecules [14], could occur before complete defect reseal and 
may eventually result in cell death. Numerous studies have reported the “delay” of injury 
development after electroporation [28], [61], [62]. Electrochemotherapy also takes 
advantage of the permeability change during electroporation to introduce cytotoxic drugs 
to kill cancer cells [14]. Studies have shown that the secondary events mentioned above 
could potentially cause more injury than primary membrane defect [61].  
 
In summary, the current understanding of IRE is that it occurs on the site of the plasma 
membrane. There tends to be general agreement of the pore formation process although 
how the membrane recovers is poorly understood and an area of ongoing research. Cell 
death may be due to lysis but predominately due to loss of homeostasis as the amount 
of mass transfer during electroporation is too difficult to overcome in cases where the 
membrane reveals. 
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Figure 1.3. Experimental observations of electroporation: (a) observation of numerous “pore-like” 
structures from rapid frozen electroporation treated sample under electron microscope [55], (b) 
volumetric response of cells during electroporation [60], and (c) sharp changes in electrical 
conductivity reflecting alteration of membrane permeability [57]. Reprinted with the permissions 
from Elsevier. 
 
1.3 In Vitro Studies of IRE 
The majority of research on in vitro electroporation was conducted before IRE was 
proposed as a tissue destruction modality. The in vitro model systems, such as cell 
suspension in cuvettes and microfluidic channels, are similar to those systems that have 
been studied for molecular biology applications, such as genetic transfection and in vitro 
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drug testing. With the development over the past several decades, much knowledge and 
insights have been gained from these studies. However, the goal of most molecular 
biology applications is to increase the uptake of desired molecules while minimizing cell 
injury. Therefore, it is beyond the scope of this paper to include all the results from in 
vitro electroporation studies. Readers may refer to [7], [63], [64] for reviews on 
progresses in these fields. In this paper, only the studies with irreversible electroporation 
(i.e. cell destruction) as the goal, or those that provided insights on electroporation 
mechanisms and are relevant to cell destructive applications are included.  
 
1.3.1 In Vitro Models 
The in vitro model systems for IRE that have been studied and published in literature 
can be classified into three categories based on the type of membrane studied [33], [65]. 
These categories include (1) artificial membrane systems, including lipid bilayer sheet 
membrane [66], [67] or vesicles [36], (2) isolated single cells [57], [68], and (3) cell 
suspension in cuvettes or microfluidic channels [17]–[20]. The artificial membrane 
models ignore the inter and intra cellular structures and therefore cannot account for 
how these structures may affect cell death pathways. However, due to their simplicity, 
artificial membrane models are easy to manipulate and image and therefore have 
contributed to numerous insights on the membrane level, such as direct observation of 
membrane surface change and measurements of defect formation timing and size [36], 
[37], [39]–[41], [66]. Single cell models isolate the individual cells from their extracellular 
environment, but provide access for cell behavior observation and direct measurements 
of electrical properties on the cellular level. Early experimental studies chose larger cells 
(e. g. muscle cells and oocytes) due to the ease of manipulation [57], [69], [70]. 
Nowadays, with the development of micro-fluidic devices, researchers are able to 
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conduct electroporation on regular sized cells (micrometer scales) using micropipette 
tips and microelectrodes [71]–[76]. The cell suspension model is the most widely used 
experimental system for in vitro cell destruction studies. It allows observation of a group 
of cells under external electrical stimulations. Here membrane or extracellular properties 
can be adjusted by changing or adding components in the medium, allowing optimization 
of IRE conditions [17]–[19], [52]. The drawback of this model is that suspension data 
reflects cell population behavior, not individual cells which require a more specialized 
microfluidic setup.  
 
1.3.2 Electroporation Time Frame 
The generation of transmembrane potential in a large lipid vesicle (~40μm) or a single 
cell (~50 μm) depends on ion concentration of the surrounding medium, but is in the 
range of micro-seconds [31], [56], [77], [78] from modeling. Electric defects occurring in 
the lipid domain are expected to reseal in milliseconds to seconds, as is the case for 
bilayer lipid membrane (BLM) or lipid vesicles [37]. Experimentally, kinetics of 
electroporation of cell membranes have been monitored by permeability, conductivity, 
fluorescence imaging, and rapid freezing electron microscopy (EM) methods [43], [44], 
[55], [79]–[85]. With permeability and conductivity measurements, a sub-microsecond 
pore initiation is recorded and confirmed by leakage experiment [82], [86]. Pore 
expansion happens in the 100 µs time range and begins to reseal (incompletely) within 
milliseconds. However, EM did not detect pore-like structures until 10 ms after the pulse 
was terminated [55], and the defects also lasted longer (up to 10 seconds) than what 
was expected for reversible electroporation voltage range (as was used in their paper). 
Another EM study observed pore structures 15mins or as long as 24 hours after IRE 
treatment in tissue [87]. One possible explanation is that the large pore-like imprints 
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imaged by the EM result from secondary effects during recovery period after pulsing, 
similar to ideas suggested by Tsong [77]. 
 
Therefore, both theoretical estimations and experimental measurements indicate that 
electroporation induced membrane events occur with a membrane charging time that is 
less than microseconds. The amount of time it takes for a membrane to bear IRE pores 
range from microseconds to milliseconds. After the external electrical simulation is 
withdrawn, it may take the membrane seconds to hours to recover if lethal damage has 
not been induced on the cell (Figure 1.4). Importantly, each of the time frames above 
depends strongly on the cell/membrane type and applied electric voltage.  
 
 
 
 
Figure 1.4. Illustration of the time frames of reversible (a) and irreversible (b) electroporations. 
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1.3.3 Injury Mechanisms and Evaluation 
As was discussed above, defect formation does not necessarily result in cell death. The 
critical cellular injury comes from either direct membrane destruction (irreversible pore, 
rupture, etc) that deployed cytoskeleton (and/or extracellular matrix connection to the 
cell through proteins), or secondary effect such as osmolarity imbalance, loss of critical 
organelles, or influx of cytotoxic molecules that eventually result in cell death. Therefore, 
it is important to examine existing in vitro injury evaluation methods and discuss their 
advantages and disadvantages. 
 
The classic membrane integrity dye assay (PI, Hoechst, Trypan blue, etc.) is simple and 
inexpensive to perform, and can detect direct membrane defects. Since most IRE 
injuries are associated with membrane defects and/or permeability change, membrane 
integrity assay is a great fit for post IRE injury evaluation.  However, two questions need 
to be carefully considered and addressed before using membrane integrity assays. 
Firstly, when is the dye introduced? As mentioned previously both reversible and 
irreversible defects are present in the membrane during IRE. If the dye is introduced 
before IRE, the “dead” cell count will be biased since cells with reversible defects are 
included in the counting even though they may eventually survive. If the dye is 
introduced after IRE, how long is the waiting period before assessment? Although it is 
difficult to measure the time for reversible defects to recover i.e. it can take seconds to 
hours, a reasonable estimation is on the scale of seconds to minutes. And it is important 
for researchers to keep this waiting period constant and report it with their experimental 
results. Secondly, how long is the dye incubation time? For instance, it is possible that 
after prolonged incubation, the secondary injury from IRE will result in cell lysis that 
would tend to increase cell death by dye count over time. Moreover, the timing of such 
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processes are unpredictable and may result in inconsistent viability results if the waiting 
period is varied. Therefore, the timing of dye application and incubation time need to be 
carefully controlled and considered when comparing results obtained from one study to 
another using membrane integrity dye assays. 
 
NAD(P)H-dependent cellular oxidoreductase enzymatic (MTT, XTT, CCK, etc.) assays 
are a class of colorimetric assays that measure the activity of cellular enzymes which 
reduce the tetrazolium based dyes via NAD(P)H-dependent metabolic activities, 
therefore reflect the number of viable cells present. The advantage of this type of assay 
is that it can detect a dead (or dying) cell under conditions others cannot. For instance, 
the dye assay can only detect cell death when the membrane is compromised whereas 
NAD(P)H can detect cell death when it is still intact. However, NAD(P)H-dependent 
assay does not have the capability to differentiate between metabolically dormant and 
dead cells. Also, environmental conditions that affect the cell metabolic activity can alter 
the cell viability results as well. 
 
ATP, or adenosine triphosphate, is a molecule found in and produced by living cells. It is 
a direct indication of biological activity and thus cell or tissue health. ATP level can be 
quantified by measuring the light emitted through its reaction with luciferase reagents 
using a luminometer. The amount of light produced is directly proportional to the amount 
of living cells present in the sample. ATP assay can suffer from similar limitations of the 
NAD(P)H-based assays in that it is unable to differentiate metabolically mute cells from 
dead ones and can also vary with the environmental conditions. 
 
 
15 
 
Table 1.1. Summary of in vitro IRE Studies 
Model System 
Electric 
Field (V/cm) 
Pulse Parameters 
Injury 
Evaluation
#
 
Ref 
Number 
Duration 
(μs^) 
Freq. 
(Hz) 
Cancer 
Cells HepG2 (liver) Cuvette 1500 30 300 0.1 a, c [19] 
 
M109 (lung) µChannel 300~400 n/a 
100ms~3
00ms n/a* a [18] 
 
DC-3F (lung) Cuvette 1200 8 99 n/s* c, e [61] 
 
Lewis (lung) Cuvette 1400 8 99 n/s  c, e [58] 
 
PC3 (prostate) Cuvette 250~2000 10~3840 100µs 10 a [17] 
 
THP-1 
(leukemia) Cuvette 1500~7500  1 
2ms or 
5ms n/a  a [20] 
 
K-562 
(leukemia ) Cuvette 1200 8 99 n/s  c, e [58] 
  Sp2 (myeloma) μSlide 2~3k 1 20 n/a a, g [88] 
Other 
Cells 
Cardiac cell 
(Frog) Single cell 0.4 V
A 
1 10ms n/a  d [57] 
 
Cardiac cell 
(Pig) Single cell 3.6
B 
2 10ms 0.2 b [68] 
 
RBC (mouse) µChannel 1100~1200 n/a  
100ms~3
00ms n/a  f [18] 
  WBC (mouse) µChannel 400~500 n/a  
100ms~3
00ms n/a  a [18] 
* n/a- not applicable, n/s- not specified 
    
 
 
 
#
  
 
a- Membrane integrity dye (PI, Hoechst, Trypan blue, etc.),  
b- Voltage sensitive dye (di-8-ANEPPS, etc.),  
c- NAD(P)H dependent cellular oxidoreductase enzymes (MTT, XTT, CCK, etc.),  
d- Electrical properties (current, voltage breakdown),  
e- ATP assay, 
f- RBC ghosts,  
g- Volumetric assay 
^ unless otherwise noted  
     
 
A-Pipette tip suction, B-chamber field 
 
1.3.4 IRE Parameters and Outcomes 
This section is an attempt to tabulate and compare the IRE parameters between the in 
vitro studies that have been published to date. Due to the wide variations of 
experimental configurations and evaluation methods, the choice of IRE parameters 
varies greatly among studies reviewed in Table 1.1. The applied electric field can range 
from hundreds to thousands of Volt/cm. The pulse number can range from 1 to more 
than 3800, and pulse duration can range from under 100 µs to 300ms. Most studies did 
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not report their pulsing frequency. In terms of injury assessment, more than half the 
studies have chosen membrane dye or NAD(P)H-based assay (or both) as their viability 
assay. Some studies have adopted the viability assay that is more specific to their chose 
of cell line (eg. the RBC ghost assay).  
 
 
 
Figure 5. Test results of PC3 cell viability after non-thermal IRE at range of fields and number of 
pulses [17]. Reprinted with permission from Elsevier. 
 
Probably the first systematic study to determine the parameters needed for IRE of 
cancer cells was performed in vitro by Rubinsky’s group using a cuvette and cell 
suspension setup [17]. In this study, the researchers tested IRE electric field strengths in 
the range of 125V/cm to 2000V/cm, and pulse number from 1 to 3840 (Figure 5). The 
pulse duration was kept constant in this study at 100 µs.  A total of 90 pulses at 250 
V/cm for 100 µs separated by 100 milliseconds were found to completely destroy 
prostate cancer cells without inducing thermal damage. What is surprising about this 
study is that within the constraint of applying electroporation with no thermal damage, 
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lower electrical fields are actually more effective for cell destruction with IRE alone than 
higher electrical fields. Also, this study did not provide data on the influence of each 
individual parameter (i.e. varying electric field, pulse number, and pulse duration 
independently while keeping the other two constant). Nevertheless, this was the 
beginning of systematic study of IRE parameters for cell destruction.  
 
A more recent overview of electroporation parameters on IRE has been presented by 
Weaver et. al. [31].  Here, combinations spanning three orders of magnitude in pulse 
strength (i.e. E-field) and nine orders of magnitude in pulse duration were discussed. For 
instance, higher field strengths (1~10kV/cm) and longer pulses (µs~ms) tends to 
necrosis, while even higher field strengths (10~100kV/cm) and shorter pulses (<µs) 
tends to apoptosis (an emerging concept called supra electroporation). Finally, lower 
field strength and short pulses tend to lead to survival. However, this appears to be in 
conflict with Rubinsky’s paper [17]. This suggests the need for simultaneously varying all 
three parameters in a single cell type to more fully explore biological response to 
electroporation parameter space (see Appendix A3). 
 
To begin asses these three parameters independently, our group recently performed a 
study on cell viability in vitro in a prostate cancer cell line (LNCaP Pro 5) and a cardiac 
cell line (HL-1) using the cuvette cell suspension setup (Figure 1.6) [89]. We observed 
that due to the stochastic nature of IRE injury, even extremely strong electric field cannot 
guarantee complete death of the entire cell population with low cumulative pulse time 
(i.e. “CPT”, pulse number multiplied by individual pulse duration). For instance in the HL-
1 case, the viability first starts to drop below 90% when electrical field exceeded 
750V/cm. This number can be considered as a lower threshold for this cell type. 
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Complete cell death (greater than 90%) can be achieved when the E-field is above 
1250V/cm given sufficient CPT. This E-field can be considered as an upper threshold. 
When the E-field is above this level, the user can be confident that complete cell death 
can be achieved as long as a sufficient CPT is given. If the strength of E-field is not a 
concern, the higher the E-field is beyond 1250V/cm, a smaller CPT is needed to achieve 
complete death. There is a grey zone between 750V/cm and 1250V/cm. In this zone, the 
cells are injured but may not actually die as a result of IRE treatment. It is worth noting 
that in our study, when the E-field is lower than 500V/cm, simply increasing the CPT 
(either pulse number or duration) does not lead to higher cell injury. This appears to be 
contradictory to the findings from Rubinsky’s study [17], in which complete cell death 
(100%) can be achieved for E-field as low as 125V/cm. However, the pulse number 
range in our study (up to 90) is far less than that in Rubinsky’s study (up to 3840). It will 
be interesting to investigate further on whether low E-field (lower than 500V/cm) can 
induce complete cell death from IRE given sufficient CPT, and how this can be related to 
clinical applications. 
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Figure 1.6. Test results of cell viabilities after IRE: (a) LNCaP Pro5 viability as a function of 
changing electric field and pulse number, pulse duration is 50µs, (b) LNCaP Pro5 viability as a 
function of changing electric field and pulse duration, pulse number is 50, (c) HL-1 viability as a 
function of changing electric field and pulse number, pulse duration is 50µs, and (d) HL-1 viability 
as a function of changing electric field and pulse duration, pulse number is 50. Injury assessment 
method for (a) and (b) is CCK-8 cell viability assay, for (c) and (d) is double dye staining assay 
(Hoescht and PI). Pulse frequency for each case is 10Hz. Each data point represents the average 
of n≥3 measurements ± SD. 
 
In summary, despite some variations, general trends do appear to hold from these 
studies. For example, the majority of field strengths used in in vitro IRE studies fall 
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between 1000~2000 V/cm, which is above the theoretical threshold calculation of 
667V/cm to induce IRE injury as discussed with Eqn(1.1) and in previous work by 
Weaver and others [33]. Although the timing and delivery pattern of the pulses can 
change, once the electric field is above the threshold for IRE, it generally takes at least 
800 µs of CPT (a combination of pulse number and duration) to achieve sufficient cell 
death. 
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Table 1.2. Summary of in Vivo IRE Studies 
Model 
Probe Design 
Field (V/cm) 
or 
Potential(V)  
Pulse Parameters 
Injury 
Evaluation 
Outcomes Ref. Type
* 
Number
/Dist. 
(mm) 
Number 
Duration 
(μs)
^
 
Freq. 
(Hz)
^
 
Normal 
Tissue 
Liver 
Rat P  2/4 1000  1 20ms n/a 
H 
Threshold: 300~500V/cm  
Lesion size: 48.6~59.6 mm
2
 
[21] 
  
V Vascular block: transient 15~20mins 
  Rat P 2/5 1500 8 100 10 
H Lesion: qualitative 
[58] 
  
E σ increase: 43+-1% 
  Rat N  
2/5 or 
2/10 
500V or 
1000V 
8 100 10 
MRI Lesion: hyperintense 
[90] 
  
H Lesion: qualitative 
  
Rabbit N  2/8 860V ~1360V  8 100 1 H Threshold: 637±43V/cm [91] 
  
Porcine N  
4/15 or 
2/25 
2500V  8 100 10 
H Threshold: 600V/cm.  
[24] 
  
US 
Lesions: hypointense during, then  
hyperintense 24hrs after IRE 
 
 Porcine 
P various 1000  
99 100 0.25~4 
H Threshold: 423±147V/cm.  
[92] 
 
N 2/5 1500 D >50% decellularized 
  
Rabbit 
and 
Porcine 
NK 1 2500V 90 100 n/s 
H, US, and TTC Lesion: qualitative 
[93] 
  
US Pores sizes from 80-490nm 
 
Brain 
Rat N  2/1 50~400V 90~180  200  
250k or 
500k  
H, MRI Lesion: qualitative 
[94] 
  
V Hi-Frequency reduces muscle contraction 
  
Dog N  2/5 
500V or 
1000V  
90 50 4 
MRI, US 
Threshold 495~510V/cm  
[23] 
  
Lesion size: 0.25~0.6cm^3 
  
MRI Lesion: hyperintense  
  
Dog N  2/5 500~1500V 80 50 
0.5, 1, 
or 4 
H, CT Lesion: qualitative 
[95] 
  
MRI 
Lesion size: 0.131 (T1) and 0.12cm^2 (T2) immed 
after IRE, hyperintense for both 
  
Dog N 1 or 500~2000V 90 50 4 H Lesion: qualitative [26] 
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2/5~10 
MRI 
Lesion size: 0.259cm^2 (500V), 0.599cm^2 
(1000), 1.665 cm^2 (1500V).  
Lesion is hypointese under T1-MRI and 
hyperintense under T2-MRI. 
 Lung Porcine N  
2/9 or 
2/15 
1500V or 
2500V  
90 70 
4 or 
ECG 
synchr
onized 
H, CT Threshold 500V/cm. Lesion size:776.4cm^3.  
[96] 
 
ECG Distance for IRE to cause heart damage: 1.7cm. 
 
Kidney Porcine NK 2/9~15 
1700V~2500
V 
90 70 4 H, CT CT imaging hypodense. [27] 
  
Porcine NK 1 or 2/15 
2700V 
(single) or 
2700V 
(paired) 
90 70 or 100 n/s H 
Lesion size: 0.38~2cm^3 (paired), 0.68~5.6cm^3 
(single). Sizes decrease over time. 
[28] 
  
Porcine NK 1 2700V 90 70ms 1.5 A 
No acute vascular damage by IRE from real-time 
DSA monitoring. 
[97] 
 
Prostate Dog N  
1, 2, or 
4/ 10~15 
1000~2000V 
1~8 
(single) 
80 
(paired) 
100 5~10 H 
Voltages lower than 1.5 kV produced little to no 
contraction in anesthetized animals and paralyzed 
animals. 
[25] 
 
Intestine Rat P  2/1 200V 50 70 4 H 
Signs of recovery showed 3 days post-surgery by 
developing and epithelial layer. 
[87] 
Implanted 
Tumor  
Mice P  2/3~5 2000 or 2500 80 
100, 800, 
or 1000 
0.03~5
k  
H, TR Up to 92% complete tumor regression (3 weeks). [22] 
  
Mice P 2/4 2500 64 100 1 H, TR 
Immune response is not instrumental in IRE 
efficacy. 
[98] 
  
Mice P 2/8 1300 8 100 1 US, TR, FI, PO Rapid decline in perfusion after IRE. [14] 
  
Mice P  2/15~30 2500 8 or 80  
100 or 
1000 
0.03~1
0 
H, E Increase of σ: 10%~180%.  [99] 
  
Mice N  1 1300V  100 100 0.3 H, TR, FI 
Threshold 1000V/cm. Lesion size: 5~8mm.  
5 in 7 cases complete regression. 
[100] 
  
Mice 
DSFC 
N  1 500V  10~99   10~100 10 H, FI 
Threshold: 600~1300V/cm.  
Lesion size: ~3.5mm radius 
[101] 
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Rat N  2/10 2500V 8 100 10 H, MRI, TR 
IRE lesion is hypointese under T1-MRI and 
hyperintense under T2-MRI.  
52% decrease in tumor size after 15 days. 
[29] 
Spontaneous 
Tumor 
Brain Dog NK 2/5 
500V and 
625V 
40 
(500V), 
80 
(625V) 
50 
ECG 
synchr
onized 
MRI, TR 
74.2% average tumor volume reduction with T1-
MRI 48hrs after IRE. 
[102] 
  
Dog NK 2/5 
625V and 
500V 
80 50 ~1 MRI, CT 
Lesion size: 0.15~0.24cm^3 for 500V and 
0.24~0.4cm^3 for 625V. 
[103] 
  
Soft 
Tissue 
Dog NK 
1 or 
2/8~15 
800V~1500V 90 70 or 100 1.5 H, CT, TR 52% volume reduction with CT 8 days after IRE. [104] 
Cardio-
vascular 
Artery Rat C /0.3 3800 10 100 10 H, VS 
VSMC 80% less 28 days after IRE, with no 
apparent damage to ECM and structure. 
[105] 
  
Rat Ca n/a 3300 10 100 10 H Ave temp increase: 0.6
o
C. [106] 
  
Rat C n/s 1750 or 2500 
10, 45 or 
90 
100 1 or 10 H, VS 
VSMC 89~94% less 28 days after IRE, with no 
apparent damage to ECM and structure. 
[107] 
  
Rat C /0.4 1700 90 100 1~4 H, VS VSMC complete ablated after 7 days. [108] 
 
 
Rat 
C /0.4 1750 
90 100 4 H, VS 
VSMC almost completely ablated after 7 days. 
[109] 
 
Ca n/a >1000 Endothelial layer regenerate by 7 days after IRE. 
  Heart Pig P  n/s 1500~2000V 
8, 16, or 
32  
total 1s to 
4s 
5 H 
Lesion size: 0.4~1.4cm depth, 3~3.5cm length, 
0.5~1.0cm width. 
[110] 
* P- plate, N- needle, NK- Nanoknife, C- clamp, Ca- catheter 
^ Unless otherwise noted    
Injury Evaluation    
H- Histology     
MRI- MRI     
U- Ultrasound     
EM- Electron microscopy   
CT- CT scanning    
ECG- ECG monitoring    
 
D- Density score    
A- Angiography     
E- Electrical properties    
TR- Tumor regression    
FI- Fluorescent imaging/ bioluminescence  
TTC-TTC Staining    
PO-Tissue oxygenation    
VSMC-Vascular smooth muscle cells count 
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1.4 Translational Studies of IRE Therapy 
Since Davalos et. al. [16] first proposed the use of electroporation as a means of soft 
tissue destruction, a great number of pre-clinical tests have been undertaken to support 
this new modality. Among them, in vivo testing on animal organs has generated the most 
abundant data and useful conclusions so far. The goal of this section is to summarize 
these experimental findings and categorize them in a manner that is readily available for 
clinicians and researchers relatively new to the field. A complete summary of these in 
vivo studies can be found in Table 1.2 and will be the basis of our discussion in the 
following sections. 
 
1.4.1 Tissue IRE Probes 
There are four major types of IRE probes: plate, needle, clamp, and catheter. Their 
popularity in usage can be found in Figure 1.7a below. The plate probe design can 
provide the most homogeneous E-field distribution to the target tissue. The E-field is 
easy to determine and is relatively well constrained between the two plates. However, 
plate probes are much more invasive if they need to be placed inside the body. Their 
usage can also be limited due to the difficulty of placement and having to maintain the 
relative parallel position between the two plates. Therefore, they are more often 
considered when the target tissue is more easily accessible (e.g. during an open 
surgery). The needle design is the most popular selection reviewed (58% of all cases) 
for tissue destruction. The needle is relatively less invasive, flexible, yet provides easy 
manipulation for placement. The number of needles can be one, two, or more (Figure 
1.7b). However, the E-field generated by needle probe(s) is not homogeneous and 
needs to be carefully calculated before treatment using advanced simulation software. 
25 
 
 
Figure 1.7. Distribution of IRE probe design and parameter choices from Table 1.2. 
(a) (b) 
(f) (e) 
(d) (c) 
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Also due to the uneven distribution of E-field around the needle, effective treatment 
volume can be small due to the restriction of the highest potential on the probe. Adding 
probe number and optimizing the probe placement can help increase the effective 
treatment volume, but that will make the treatment more invasive as well. A clamp probe 
design can also be more invasive and suffers similar limitations as the plate probe. 
However, they can provide more secure contact that can work better for specific organs, 
such as arteries and intestines during open surgery. The catheter probes are also 
designed for tubular organs. They require more skill to manipulate and navigate to the 
target site but can be the least invasive compared to other probe designs. 
 
Several researchers have expressed concerns about the impact of probe size to the 
actual treatment volume. This issue is relevant to the needle probe design. It has been 
found [91], [111] that the smaller the diameter of the needle electrode, the higher the 
voltage that has to be applied to obtain the same electric field intensity in the vicinity of 
the electrode. According to Laplace equation, the E-field drops exponentially with the 
distance away from the electrode. However, such drop is steeper with a smaller 
electrode diameter. Therefore, the size of the probe matters for the distribution of the E- 
field strength and needs to be accounted for in the calculation.  
 
When multiple probes are used, the distance between the probes (Figure 1.7c) also 
needs to be accounted for in the E-field calculation and treatment planning. Another 
important safety factor for probe placement is the impact of the distance from the IRE 
probe to critical organs. As in the case for the heart, Deodhar et. al. [96] has found that 
within 1.7cm from the heart, fatal events occurred with all unsynchronized IRE in a study 
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of 11 pigs with lung and myocardium tissue destructions. ECG synchronized IRE 
delivery could avoid significant cardiac arrhythmias although minor events still present. 
 
1.4.2 IRE Pulse Parameters (E-field applied, pulse duration, and pulse number) 
The three most critical parameters affecting outcome of IRE are the E-field strength, 
pulse duration, and pulse number (Figure 1.7d~1.7f). The E-field used by the studies 
surveyed in Table 1.2 are summarized and compared below in Figure 1.7d. It can be 
seen that the majority (89%) of researchers used an E-field above 1000V/cm and below 
2500V/cm for tissue destruction. This agrees well with in vitro work in Figure 1.6 
(1250V/cm threshold for complete cell death). The pulse durations ranged from 50 to 
100 µs in 87% of the studies reviewed (Figure 1.7e).  And finally, the pulse number 
ranged between 10 and 90 for most studies (Figure 1.7f).  As was discussed in our in 
vitro section, it requires a certain amount of cumulative pulse time to achieve complete 
cell death even when above threshold E-field level. This can be achieved by either 
increasing the pulse duration or the total pulse number. However, there are constraints 
on increasing pulse duration due to Joule heating (i.e. thermal effects), and procedure 
time is lengthened by increasing pulse number. 
 
1.4.3 Injury Evaluation 
The injury evaluation in tissue is more complex than in vitro or cell cases. For instance, 
the injury can be monitored in real time intra-operatively or after a procedure in an acute 
or chronic manner. The injury can also be screened on live animals, or examined post-
mortem. The injury evaluation method used are summarized in Figure 1.8. 
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Figure 8. Choices of injury evaluation method for in vivo IRE studies from Table 2. *Optical 
imaging methods are limited by penetration depth, and therefore are used predominantly in intravital 
chamber systems. [52], [101], [112] 
 
MRI, Ultrasound, and CT scanning are all direct, non-invasive imaging methods for live 
animals. They can be performed any time before, during, or after the procedure. A good 
review on imaging methods for IRE tumor treatments are given in [113]. Using these 
modalities, the IRE lesion is reported to be hypointense under T1-MRI and hyperintense 
under T2-MRI by Guo et al [29] and hyperintense for both TI and T2 MRI in [23], [95]. 
Lesions were reported to be hypointense during, and hyperintense 24hrs after IRE from 
untrasound monitoring [24], [114], [115]. For CT results, both intraoperative and follow 
up scans found hypodense nonenhancing lesion [27]. Not all studies have reported 
detailed description of their imaging results, and disagreement can be found in some 
studies. 
 
Histological assessment of (usually H&E) stained samples is the most used evaluation 
method for IRE therapy post mortem [24], [58], [90], [91]. The lesion volume measured 
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from the histology sample can vary greatly depending on the time after IRE treatment, as 
was described as injury development in vivo [24], [105]. In general, follow up to a 
minimum of 3 days is necessary to evaluate the injury development unless only acute 
injury is of interest.  
 
TTC, or Triphenyl tetrazolium chloride staining is another evaluation method for IRE 
injury post mortem. It is similar to the NAD(P)H-based assay for in vitro assessment and 
is used to differentiate metabolically active and inactive tissues. Compared to histology 
staining, TTC is faster and less expensive. However, the TTC stained samples cannot 
be stored and used at a later time like the histology samples. Both the start and 
incubation timing can affect the viability results. Therefore, careful study must be done to 
get the optimal assessment timing for a specific type of tissue [116], [117].  
 
Optical imaging uses fluorescent dyes in an intravital method (i.e. dorsal skin fold) to 
examine the perfusion defect in tissue after IRE treatment. It measures the IRE injury at 
the tissue level. Like the histological assessment, optical imaging results can also 
change as the injury develops in tissue. However, since the same animal can be imaged 
respectively over time, optical imaging requires much less animals and money to study 
the injury development pattern compared to histology [52], [101], [118].  
 
Tumor regression is another method to determine the treatment efficacy of IRE. 
Although tumor regression results have been reported in some studies [100], [102], 
[114], large scale, randomized animal studies are still not available on IRE therapy at 
this time.  
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Since IRE is still more often used in combination with chemotherapy or other 
enhancement reagents, the influence of chemo drug (bleomycin or other cytotoxic 
agents) or adjuvants on the viability results needs to be carefully accounted for. 
Specifically, it is important not to confuse the combinatorial IRE therapy outcomes with 
independent IRE monotherapy, as the results of the two are not directly comparable. 
 
1.4.4 Outcomes and Thresholds 
The IRE thresholds are mainly determined by overlapping the modeled electric field 
distribution with the lesion volume measured from viability studies. Most in vivo studies 
have found the threshold to be 500~1000V/cm (Table 1.2), which agrees well with the in 
vitro results we have reviewed in Table 1.1. The lesion size determined by these studies 
varies greatly due to different viability assays, different evaluation timing (intra-operative, 
after, etc.) and different tissue/animal subject. But generally, the IRE treatment volume is 
relatively small in our surveyed studies [26], [29], [57], [110]. Although one could 
consider the use of high voltages in the living body to be a safety concern, it is important 
to realize that the energy delivered is extremely low due to the short duration of the 
pulses. IRE uses was shown to be safe during tissue destruction in the studies surveyed 
here. Specifically, all animals treated with IRE survived after the treatment and only few 
cases have reported side effects associated with electrical shocking such as temporal 
muscle contraction and arrhythmia [24], [96]. More recent studies have adopted ECG 
synchronized IRE combined with general anesthesia to address the above side effects. 
 
1.5 Clinical Results 
IRE has been used clinically for more than fifteen years in combination with chemo 
therapy, and is on the rise as a monotherapy over the last five years. Internationally, 
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there are a number of ongoing clinical trials of IRE therapy [119]–[126] also reviewed in 
Table 1.3. For instance, Gothelf et al., [13] reviewed IRE electrode placement, field 
strength of pulses, drug delivery, anesthesia, and treatment evaluation for animal & 
human clinical trials. However, the studies covered in Gothelf’s review were based on 
electrochemotherapy and all results were a combinational result of IRE injury with 
bleomycin. In 2010, Pech et. al. [120] (U of Magdeburg) reported the first in-man clinical 
study with IRE treatment on kidney (n=6). The study was for safety verification only. The 
tumors were surgically resected 5 minutes after IRE, and no treatment protocol was 
recorded in that paper. In 2011, Thomson et al. [121] published a larger scale of studies 
on various organs (clinical studies done in Australia). They investigated ECG 
synchronized IRE in 38 humans with advanced malignancy of liver (n=25), kidney (n=7), 
and lung (n=3), a total of 69 separate tumors (average=46cm3). Complete tumor 
destruction verified by CT was achieved in 66% (46/69) tumors without IRE related 
adverse event. Complications found in this study include cardiac arrhythmia, temporary 
plexus injury, partial ureteric obstruction, and short term post procedure pain. In 2013, 
Cheung et. al. [125] (Australia) reported another IRE study on 11 patients with 18 
unresectable hepatocellular carcinoma that were not RF suitable. The mean follow-up 
time period was 18 months. 13 of the 18 (72%) lesions were completely ablated with 
93% success for lesions ≤ 3 cm (13/14). The local recurrence-free period was 18 ± 4 
months and the distance recurrence free period was 14 ± 6 months. No serious 
complications were observed in this study, although minor complications were found 
such as transient urinary retention, transient local post-procedure pain, and lesions lying 
adjacent to important structures or organs. In 2014, Neal et. al. [127] (Australia) reported 
two cases on IRE treatment of prostate cancer 3~4 weeks before surgical resection to 
evaluate safety and characterize the relevant properties to improve treatment planning 
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and outcome predictions. IRE has also been investigated for locally advanced pancreatic 
cancer in a series of studies by Martin et. al. [126], [128] and found to be safe and 
effective. 
 
 
 
Figure 1.9. Numbers of IRE clinical trials that are recruiting patients and registered in the United 
States from Table 1.3. 
 
A further list of organizations pursuing IRE clinical trials that are recruiting patients and 
registered in the United States can be found in Table 1.3. From this table, we can see 
that the number and scale of clinical studies on IRE have greatly increased since 2013 
(Figure 1.9). Many of the studies on this list are still ongoing, and published results are 
not yet available. Hopefully, the published results will yield systematic observations that 
validate the use of IRE in the clinic. 
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Table 1.3. Clinical trials of independent IRE studies registered on clinictrials.gov 
 
NCT Study # 
Start/Finish 
Time 
Patient 
# 
Country  Targets 
Endpoint 
Classification 
(Phase #) 
NCT01078415 
Feb 2010,  
Oct 2011  
25 
France, 
Germany, 
Italy, Spain 
Carcinoma, Hepatocellular S/E 
NCT01442324 
Feb 2011, 
Sep 2012 
5 Italy 
Metastatic Liver Cancer;    
Cholangiocarcinoma;   
Neoplasm Metastasis 
S/E 
NCT01369420 
May 2011, 
Dec 2011 
10 Italy Pancreatic Adenocarcinoma S (2) 
NCT02010801 
Apr 2012,  
Dec 2013 
20 Taiwan Malignant Liver Tumors n/a 
NCT01799044 
Nov 2012, 
Sep 2013 
10 Netherlands 
Colorectal Liver Metastases;    
Metastatic Liver Disease 
S/E (1) 
NCT01790451 
Aug 2013, 
Mar 2014 
16 Netherlands Prostate Cancer S/E (1) 
NCT01939665 
Sep 2013, 
Sep 2014 
10 Netherlands 
Locally Advanced Pancreatic  
Carcinoma (LAPC);  
Non-metastasized Unresectable 
Pancreatic carcinoma;    
Pancreatic Cancer 
S/E (1,2) 
NCT01726894 
Oct 2013,  
Apr 2015 
20 UK Prostate Cancer n/a 
NCT01967407 
Oct 2013, 
Dec 2015 
20 Germany 
Kidney Tumor;    
Renal Cell Cancer 
E (1,2) 
NCT01972867 
Nov 2013, 
July 2014 
6 US Prostate Cancer S 
NCT01835977 
Jan 2014,  
Jan 2018 
200 Netherlands Prostate Cancer S/E (2) 
 
S-Safety, E-Efficacy 
 
1.6 Limitations and Challenges of IRE 
Despite the advantage and progress discussed above, IRE is still not the preferred 
choice of treatment for most diseases.  IRE is usually considered only when other 
therapies are not applicable or fail to show an improvement. This lack of acceptance of 
IRE within the medical community is due in part to the status of development of the 
technology, and to several issues with the outcomes of IRE. Specifically, IRE has shown 
an inability to destroy large volumes of tissues without repeats or repositioning the 
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electrodes. This is an important limitation that remains to be fully addressed. For 
instance, the common lesion sizes reported in literature without repeats or repositioning 
the electrodes are still relatively small [26], [29], [57], [110]. This is because extremely 
high electric field needed to created larger lesions (greater than 2500 V/cm) cannot be 
applied clinically without  damage to adjacent nerves and the cardiovascular system 
[96], [129]. Thus, using multiple probes or repeat treatment with repositioned probes are 
ways to increase the lesion size. Theoretically, with well-planned probe layouts, a larger 
and customized lesion could be achieved fitting the exact geometry of the target tumor. 
However, the addition of multiple probes increases the complexity and difficulty of the 
procedure, and makes the treatment more invasive to the patient.  
 
A further limitation is the heterogeneity of injury within the target treatment zone. For 
instance, some studies [29], [101] show that incomplete treatment (live tumor patches in 
a target treated zone) have been found after IRE. This phenomenon is a real concern for 
cancer treatments due to the likelihood of recurrence, and if unresolved, represents a 
threat to the eventual translation of IRE. Importantly, local recurrence after hyperthermia 
and cryosurgery is significant and reported in the clinical literature [130]–[132]. However, 
having studied pre-clinical lesions for IRE, heat and cryo in an identical animal model, 
the appearance of live tumor patches within the treated tumor volume (rather than at the 
boundary) appears at this stage to be unique for electroporation [101], [133]. It is 
possible that the live cell patches are a result of local electrical property heterogeneity 
within the tumor tissue thereby lowering the effective electric field in the target region 
[134]. Thus, the challenge to improve the reliability of IRE cancer therapy calls for 
methods of enhancement that can ensure the electric field distribution over the entire 
target region is above the IRE threshold. 
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1.7 Potential Enhancement Approaches 
1.7.1 Cytotoxic Agents 
Perhaps in recognition of the smaller volume or potential for heterogeneous response 
within the tissue, several groups have already championed a combinatorial approach as 
mentioned earlier in the review entitled: “electrochemotherapy”. This method uses 
electroporation to open the membranes to allow chemotherapeutics such as bleomycin 
which are normally not taken up by cells to more easily internalize and destroy cells [13], 
[14]. A similar method proposed by Frandsen et. al. [61] uses direct intratumoral calcium 
injection followed by electroporation, leading to lethal intracellular calcium events. While 
promising, cytotoxic drug or molecules are still limited by the dose and side effects, thus 
further methods remain of interest to research and clinical groups. 
 
1.7.2 Use of High-Frequency IRE 
High-Frequency IRE (H-FIRE) is also a promising approach that could enhance the 
treatment outcome of IRE therapy. Unlike conventional IRE, H-FIRE protocols involve 
the use of microsecond bursts of bipolar pulses on the order of 500ns-5us, delivered at a 
pulse repetition rate of 1 Hz [94], [135]. The benefit of high-frequency IRE is that it 
provides the ability to administer IRE therapy without the use of neuroblocking agents to 
mitigate muscle contractions during the procedure [94]. In addition, high-frequency fields 
have the potential to overcome impedance barriers posed by low conductivity tissues, 
which could provide more predictable lesion volumes by mitigating the effects of patient-
to-patient tissue variability, conductivity changes due to electroporation, and tissue 
heterogeneities [135]. H-FIRE is a relatively unexplored area of research at this moment 
[31] and future work is needed to elucidate the relationship between H-FIRE parameters 
and treatment volumes. 
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1.7.3 Membrane Modifications 
Another class of studies focuses on enhancing the destructive efficacy of IRE itself 
without relying on chemotherapeutic drugs or cytotoxic agents to enter and kill the 
cancer cells. Specifically, approaches that directly modify membrane properties (i.e. line 
tension and surface tension) with surfactants, impeding the resealing process (big 
molecules, channel holders, etc), and fine tuning the pulse timing have all been tried and 
shown effective in enhancing the IRE destructive potential, as was summarized in Table 
1.4.  
 
Specifically, a study on IRE enhancement with DMSO has shown that over 60% 
increase in cell destruction in vitro and greater than 136% increase in treatment volume 
in vivo can be achieved by adding 5% volume percentage of DMSO to the cell 
suspension or perfused into the tissue [52]. Another study on lipid bilayer model has 
shown that as low as 0.1µM of C12E8 can lower the IRE transmembrane voltage 
threshold from 450mV to 333mV with their experiment setup [66]. Moreover, studies 
have shown that the pulse timing method can increase the cell destruction by 67% in 
vitro [136] and tissue destruction volume by 101% in vivo [52], respectively. Because the 
pulse timing approach does not introduce any foreign molecules into the body, it 
enhances the efficacy of IRE with virtually no additional cost (except for slightly longer 
procedure time) and can be combined with any existing treatment or enhancement 
protocols. 
 
The number and variety of studies on IRE enhancement is still limited at this time. 
However, it is a promising path to follow and can greatly increase the acceptance and 
capability of IRE tissue destruction for clinical applications. 
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Table 1.4. Membrane targeted enhancements for IRE 
 
 
Model Adjuvant Dose Timing 
Injury 
Evaluation 
Indications Ref. 
Surfactant 
addition 
Prostate 
cancer 
cells 
DMSO 
1% ~15% 
v/v  
1 min 
before IRE 
PI and 
Hoechst 
>75% increase in 
cell destruction 
[136] 
Mice 
DSFC 
tumor 
DMSO 5% v/v 
6 min 
before IRE 
Histology, 
intravital 
imaging 
>136% increase 
in injury volume  
[52] 
Lipid 
bilayer 
C12E8 
conc. 
dependent, 
but worked 
as low as 
0.1uM 
  
Lower threshold 
voltage  
[66] 
Pig skin 
SDS 
(sodium 
dodecyl 
sulfate) 
    
 [137], 
[138] 
Channel 
effect  
Lipid 
bilayer 
Gramicidin 
D 
conc. 
>1:500    
Increase 
threshold voltage 
[67] 
Lipid 
bilayer 
a-
hemolysin     
[139] 
Pore holder  
Pig skin Heparin 
    
[140] 
Pig skin 
Sodium 
thiosulfate     
[141] 
Pulse 
timing  
Prostate 
cancer 
cells 
  
3 trains with 
10s~2mins 
delays 
PI and 
Hoechst 
>67% increase in 
cell destruction 
[136] 
Mice 
DSFC 
tumor 
  
3 trains with 
30s delays 
Histology, 
intravital 
imaging 
>101% increase 
in injury volume  
[52] 
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2.1 Introduction 
Electroporation, or electropermeabilization, is a promising technology that induces 
significant increase in conductivity and permeability of the plasma membrane by 
exposing the cells to a series of short, high-voltage electric pulses [1]. It has been widely 
used in molecular biology as a method to introduce foreign molecules, including ions, 
dyes, antibodies, RNA and DNA fragments, into living cells thereby supporting fields 
such as drug delivery and gene transfer [6], [7].  Recently, Davalos, Rubinsky, and Mir 
[16] proposed the use of electroporation as a means of soft tissue destruction, 
sometimes termed “ablation” in the medical community. Pre-clinical testing in vitro [19] 
and in vivo [21], [22], [110] has been undertaken to support this new modality. Unlike 
traditional electroporation, where cells are only expected to be temporarily permeabilized 
and recover after the treatment; irreversible, or lethal poration is the goal in cancer 
therapy applications. Therefore, the term “irreversible electroporation” (IRE) is used to 
distinguish this approach. The purported benefits of IRE are that it is simpler and faster 
while maintaining the minimally invasive nature of existing thermal therapies (i.e. RF and 
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cryosurgery). Electric pulses of IRE are normally delivered by millimeter-sized probes 
and take only seconds to deliver. In addition, in vivo studies have shown that the 
demarcation between live and treated tissue (usually referred to as the “transition zone”) 
is sharper compared with thermal therapies [24], [142]. It has also been suggested that 
IRE could destroy tumor cells while preserving tissue structures such as major ducts and 
vessels within the target region [24]. Being a non-thermal therapy [143], [144], IRE is 
free from the heat sink effect of local vascular systems, which helps future clinical 
planning as it is less dependent on perfusion (currently a limiting issue in thermal 
therapies [25], [145]), making IRE a superior candidate for tumors that are adjacent to 
major blood vessels or ducts.   
 
A wide variety of cell [17]–[20], [57], [68], organ [26]–[28], and animal [21], [24], [29] 
models have been used to characterize IRE in different cancer types. The first in-man 
phase I clinical trial [120] has also been conducted on patients with renal cell carcinoma. 
No significant safety issues were noted based on hematological, serum biochemical and 
ECG recordings of the patients, although long-term effects remain to be studied in larger 
clinical trials. More recent clinical trials have been reviewed in [30]. However, despite 
these encouraging results reported, there are several limitations with this emerging 
technique, which could present hurdles to its clinical translation. Perhaps the most 
critical one is the inability of IRE to destroy large volumes of tissue under a safe electric 
field strength level. For instance, the common lesion sizes reported in the literature with 
double needle probes are currently small [26], [29], [57], [110]. While it is possible to 
enlarge the treatment volume by increasing the voltage on the central electrode, 
extremely high electric fields (greater than 2500V/cm) are needed and not appropriate 
for clinical application as adjacent nerves and the cardiovascular tissue may be 
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damaged with such high fields [96], [129]. Using multiple probes is another way to 
increase lesion size. Theoretically, with well-planned probe layouts, a larger and 
customized lesion could be achieved fitting the exact geometry of the target tumor. 
However, the addition of multiple probes not only makes the treatment more invasive to 
the patient, but also increases the complexity of the operation procedure, making IRE a 
less attractive approach to the surgeon.  
 
 
Figure 2.1. Reported IRE enhancement strategies: (a) competing factors (surface tension and 
edge line tension) during pore formation, (b) nucleation based energy model and critical pore 
radius & energy, and (c) illustration of the pulse timing delivery method 
 
There are several approaches to expand the tissue volume that can be treated by 
electroporation including the addition of chemotherapeutic or cytotoxic agents, and 
approaches that increase electropermeabilization of the membrane. Combining 
chemotherapy with IRE has been championed by several groups and is referred to as 
“electrochemotherapies” [13], [14]. A similar method was also proposed recently by 
Frandsen et al. [61] using direct intratumoral calcium injection followed by 
electroporation, which led to lethal intracellular calcium events. While these studies 
demonstrated improved cell killing, the focus was on enhancing the ability of 
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chemotherapeutic drugs or cytotoxic agents to enter and kill the cancer cells rather than 
enhancing the efficacy of IRE itself. However, the aim of this study is to investigate the 
ability to increase the destructive ability of IRE without relying on cytotoxic drugs. 
Specifically, mechanisms that directly modify membrane properties (i.e. line tension and 
surface tension, See Figure 2.1a) should reduce the voltage threshold for lethal 
permeabilization and therefore increase the efficacy of cell killing and therefore the 
volume treated after a given IRE. Two methods to achieve these changes are proposed 
in this study: 1) addition of surfactant (e.g. Dimethyl sulfoxide, or DMSO) to directly 
interact with membrane lipids thereby changing membrane line tension and surface 
tension, Figure 2.1b, and 2) use of pulse timing (i.e. introduction and persistence of 
defects in the membrane between pulses, Figure 2.1c). Experimental studies were 
conducted on a human prostate cancer model (LNCaP Pro 5) under both in vitro (cell 
suspension) and in vivo (Dorsal Skin Fold Chamber) conditions, both with multiple 
viability assessment methods to evaluate and compare the injury levels with or without 
IRE enhancement. Here, we document that both of the two non-toxic approaches we 
propose (surfactant adjuvant and pulse timing) can be highly effective in enhancing the 
destructive potential of IRE in vitro and in vivo. Furthermore, the mechanism of 
enhancement is shown to be linked to membrane stability thereby allowing a reduction in 
the energy barrier required for irreversible pore formation. 
 
2.2 Materials and Methods 
2.2.1 Tumor Cell Culture 
The prostate cancer cell line (LNCaP Pro 5) was cultured as adherent monolayer in 
Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 (BD Biosciences, CA) supplemented 
with 10% fetal bovine serum, 100U/ml of Penicillin/Streptomycin (P4333, Sigma-Aldrich, 
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MO), and 10-9 mol/L dihydrotestosterone (DHT) as previously described [112]. When 
>85% confluence was reached, the cells were detached by adding 0.05% Trypsin-EDTA 
(Invitrogen, CA) and then made into a single cell suspension.  
 
 
Figure 2.2. Experiment setup for in vitro IRE system: (a) Schematic graph of the IRE cuvette 
system, (b) electric field distribution over the cuvette gap with 200V applied across the gap, (c) 
temperature change after baseline IRE treatment; and in vivo IRE system: (d) Schematic graph of 
the chamber surface layouts, (e) electric field distribution over the chamber with 500V applied on 
the center electrode, and (f) temperature change after baseline IRE treatment 
 
2.2.2 In vitro Electroporation 
For each in vitro electroporation test, 400 µl of the prepared cell suspension (0.5~0.6 
million cells/ml) was pipetted into the electrode gap (2 mm) in an electroporation cuvette 
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(FB102, Fisher Scientific), which was then placed in an external electric field created by 
an electric pulse generator (BTX ECM 830, Harvard Apparatus), as is shown in Figure 
2.2a. The pulsing frequency is 10Hz unless otherwise specified. The output voltage and 
current were monitored by an oscilloscope (Tektronix TDS 2002).  
 
2.2.3 Enhancements 
DMSO enhancement was achieved by first incubating the cell suspension with DMSO at 
1% to 15% volume fraction (v/v) before IRE treatment. This incubation lasted for 1 
minute to allow sufficient diffusion of DMSO molecules into the cell membrane while 
showing minimal toxicity to cells as compared to controls (supplementary information, 
S2.1). To reduce the impact of DMSO on extracellular electrical conductivity during IRE 
or toxicity after, the cell suspension was diluted below 1% v/v immediately before the 
IRE procedure. All groups in Figure 2.5 were exposed to one train of 50 pulses (200V, 
50μs per pulse).  
 
With pulse timing, the total energy delivered (511 pulses, 200V, and 50μs per pulse) was 
the same throughout the experiment groups. However, the 51 pulses were divided into 3 
trains of 17 pulses with varied delays in between trains (10s, 30s, 1min, and 2 min). The 
pulse timing delivery method is illustrated in Figure 2.1c. 
 
2.2.4 In vitro Viability Assay 
In vitro cell viability for experimental and control groups were evaluated using a 
Tetrazolium-based CCK-8 assay (Dojindo Molecular Technologies, Inc) that measures 
the dehydrogenase enzymatic activity associated with metabolic processes in live cells. 
                                                        
1
 We chose to use 51 pulses in the pulse timing method so that the same number of pulses (17) can be 
delivered in each train. The dose difference between 51 and 50 pulses in our baseline groups is marginal. 
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The cell suspensions were electroporated as described above. After IRE, 100 μl aliquots 
of the cell suspensions were mixed with 10 μl of CCK-8 reagent in a 96 well plate and 
incubated for 4 hours at 37 degrees Celsius in the incubator with 5% CO2. The optical 
absorption of the sample (Figure 2.3a) was then read in a spectrophotometer (Synergy, 
BioTek Inc., VT) at a wavelength of 450 nm to determine the viability according to a 
standard protocol as outlined in the manufacturer’s manual. The viability results were 
presented as a standardized (or normalized) percentage value with respect to the 
controls. By membrane dye (Hoechst, PI), the viability of controls was consistently 96±3 
%. 
 
Figure 2.3. Injury assessment for the in vitro IRE system with the CCK-8 cell viability assay (a);  
and for the in vivo IRE system injury evaluation by perfusion defect characterization from the 
intravital microscopy (b), and  necrosis characterization from the histological image (c) 
 
2.2.5 In Vivo Tumor Cell Seeding and Growth 
The DSFC tumor system is a two dimensional, controlled environment in which tumor 
growth is restricted between two anodized aluminum frames, separated by a small 
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distance of 0.5 mm maintained by spacers on the screws [133]. The frames with a 10 
mm diameter viewing window are implanted on the dorsal skin of the animal. The DSFC 
chambers were implanted in nude mice (Jackson Laboratory, Bar Harbor, ME) as 
previously described in [133]. In brief, the skin on the back of the mouse was 
sandwiched between the chambers. The skin on the viewing side was removed to 
expose the dermis with microvasculature on the opposite side. For clear visualization, 
excess fascia on the dermis was removed. A quartz glass microslide was used to cover 
the viewing side of the window to reduce evaporation and keep the tissue sterile during 
the experiment. All animal usage and experimental procedure protocols were approved 
by the Institutional Animal Care and Use Committee of the University of Minnesota. 
 
2.2.6 In Vivo Electroporation 
For in vivo electroporation, a needle electrode (d=1mm) was inserted through the tumor 
and skin in the center of the DSFC window and a ring electrode connected to the edge 
of the chamber (thickness = 1mm and height = 2.5mm), as is shown in Figure 2.2d and 
previously reported by Qin [101]. An insulating layer was placed around the ring 
electrode to avoid arc formation. The applied voltage and current were monitored by 
oscilloscope (Tektronix TDS 2002). The pulsing frequency is 10Hz unless otherwise 
specified. An infra-red (IR) camera was also used to record the temperature from the top 
surface of the tumor. 
 
2.2.7 Enhancements 
For DMSO enhancement, 20 μl of DMSO dilution (5% v/v) in 0.9% saline was applied 
topically over the DSFC tumor surface. This concentration was determined based on our 
best results from the in vitro experiments (Figure 2.5). The dilution was left on the 
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window for 6 minutes (see supplementary information, S2.2 for calculation of diffusion 
time) to allow for diffusion within the tumor volume before electroporation. 
Electroporation was performed in one train of 50 pulses (500V, 50μs per pulse).  
 
To assess the impact of pulse timing, 51 total IRE pulses (500V, 50μs per pulse) were 
divided into 3 trains of 17 pulses with delays of 30 seconds in between trains. This 
delivery pattern was determined based on our best results from the in vitro experiments 
suggesting no further benefit to longer pulse delays (Figure 2.5b).  
 
2.2.8 In Vivo Viability Assessments  
The perfusion defect after either DMSO or pulse timing enhancement was visualized by 
intravital fluorescent microscopy and recorded before treatments, and immediately, 1 
day and 3 days after the treatments. The animals were sacrificed on day 3, and tumors 
were taken for histological staining and evaluation.  Perfusion defect (or vascular stasis) 
can be measured by the lack of fluorescence within a vessel after intravenous injection 
of a fluorescent dye [101]. The perfusion defect of the electroporated (or control) tumor 
microvasculature was visualized after 10mg/ml 70-kDa FITC–labeled dextran was 
administered by tail vein injection. The anesthetized animals were fixed on a specially 
designed mouse stage which was mounted to an inverted fluorescence microscope 
(Figure 2.3b). The DSFC is traversed radially in four perpendicular directions (north, 
south, east, and west) while radial locations of stasis were noted using a micrometer 
scale fixed on the stage with the chamber center as the origin. This technique has been 
used extensively by our group [101], [112]. The animals were sacrificed 3 days after IRE 
(or IRE plus enhancement) treatment and the tumors were removed and fixed in 10% 
buffered formalin for 48 hours. The tumor samples were then embedded in paraffin, 
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sectioned at 5µm, and stained with Hematoxylin-Eosin (H&E) dye. The whole tumor 
section was imaged under a stereomicroscope with a large field of view (Leica MZ FL III 
fluorescence stereomicroscope) to examine the entire tumor area. Images were taken 
and then processed using Image J to trace the region of necrosis demonstrating 
destruction (Figure 2.3c).  
 
2.2.9 Data Analysis and Statistics 
Group numbers of n≥4 and n≥8 were achieved for all of our in vitro and in vivo 
experiments, respectively. The results are presented as average values ± standard 
deviations. The student t-test was performed between experimental and control groups 
where P value ≤ 0.01 was taken to delineate statistical significance between groups. The 
IRE parameters used in the above experimental models and conditions are summarized 
in Table 2.1. 
 
Table 2.1. Summary of experiment conditions and enhancement outcomes 
 
 
2.3 Modeling 
2.3.1 Membrane Poration Model 
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Arguably, the most critical cellular response to IRE is the permeabilization of the cell 
membrane during electric pulsing as shown in Figure 2.1. Previous studies have shown 
that the likelihood of membrane rupture during electroporation is closely associated with 
the energy dynamics under an external electric field [54]. The free energy (   ) 
associated with pore formation on the cell membrane can be modeled with a modified 
nucleation model [33] as described in Eqn (2.1): 
 
                             (2.1) 
 
The creation of membrane pores during IRE depends on the free energy (  ) of pore 
formation on the cell membrane (See Eqn 2.1). When the pore exceeds a critical radius 
( ∗ , the free energy decreases as the pore expands, which further induces membrane 
rupture and leads to cell death. In other words,    works as an energy barrier for the 
pore formation. When an external electric field is applied across the cell membrane (  
>0), the energy barrier for such a critical pore to develop is decreased, which explains 
why electroporation can greatly increase the permeability of the cell membrane. 
 
However, the increase of transmembrane voltage is not the only approach to reduce the 
energy barrier in this model. As shown in Eqn 2.1, decreasing the edge line tension   
can also alter the free energy of pore formation (  ) and thus greatly impact the pore 
formation process. According to the membrane elastic model by Karatekin [146], the 
membrane edge line tension   is influenced by its bending modulus  , the membrane 
thickness  , the inclusion fraction   of foreign molecules, and the spontaneous curvature 
    of the included molecules, as in Eqn (2.2): 
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      (
 
 
     ) (2.2) 
 
Interestingly, earlier studies have shown that the addition of certain surfactants and 
peptides can reduce the threshold of electroporation in artificial membrane systems [66], 
[67], [147]. An example of this surfactant group is DMSO. When absorbed in the head 
regions of the lipid bilayer, they can help lower the edge line tension ( ) by decreasing 
the bending modulus ( ) and introducing positive curvature ( ∗   ) groups. Molecular 
dynamics simulation in [148] has demonstrated that 11.3 mol % DMSO leads to over 
90% decrease in line tension on modeled lipid bilayer membrane, which may cause a 
significant reduction of IRE threshold (Figure 2.1b). 
 
2.3.2 Electrical and Thermal Models 
The electric field distributions in our in vitro and in vivo systems were modeled using 
COMSOL Multiphysics software. For the electroporation cuvette, the electric field is 
considered homogeneous across the 2 mm gap and generates 1000V/cm E- field with 
the 200V pulses as shown in Figure 2.2b. The E-field distribution in the DSFC is 
determined by Laplace equation (Eqn (2.3)): 
 
            (2.3) 
 
where Ω is the electrical conductivity of tumor,   is the electric potential. For 
homogeneous tissue, the electric field calculated from Eqn (2.3) shown in Figure 2.2e.   
When neglecting heat losses, the energy from electric current all goes to tissue heating, 
which is illustrated by:  
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       |  |  (2.4) 
 
Using the bioheat equation implemented in COMSOL by adding a heating term (SAR in 
Eqn (2.4)) from the electric pulsing: 
 
 
   
  
  
                          
        (2.5) 
 
where  ,   , and   are density, heat capacity and temperature of the tissue,    ,      , 
and    are density, flow rate, heat capacity and temperature of the blood, and  
    is 
metabolic heat. In the in vitro case, the blood flow and metabolic heat terms were set 
zero. The parameters used in our models are summarized in Table 2.2. This model 
allows the temperature rise after IRE pulsing to be captured as shown in Figure 2.2c and 
2.2f. It is worth noting that the conductivity of tissue will increase during IRE due to 
electroporation’s permeabilization effect which has been noted in previous work from our 
lab [101].  We have elected not to pursue this here in order to focus solely on the impact 
of DMSO and pulse timing without the confounding effects of conductivity change.   
Certainly more careful study is warranted in the future. 
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Table 2.2. Summary of parameters used in our models 
 
 
2.4 Results 
2.4.1 In vitro Enhancement 
The results obtained with proposed enhancement strategies will be compared with a 
“baseline electroporation”. Specifically, a baseline dose was established which achieved 
close to 50% cell death after IRE. Here we based the dose on the pulse number while 
holding other parameters fixed. For instance, the electric voltage, pulse duration, and 
frequency were fixed at 200V (over the 2 mm cuvette gap), 50 μs, and 10Hz and then 
the pulse number was increased from 10 to 99 times. This showed a dose-dependent 
decrease in cell viability after electroporation (Figure 2.4). Based on this data we chose 
50 pulses as our baseline dose (i.e. 50% cell destruction) after IRE. 
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Figure 2.4. . Baseline viability results after IRE treatment in vitro. Each data point represents the 
average of n=4 measurements ± SD  
 
The change of cell viability with the addition of DMSO alone was negligible when 
concentrations were under 5% v/v (supplementary information, S1). However, when 
combined with IRE pulsing, the cell viabilities dropped significantly as DMSO 
concentration was increased (Figure 2.5). A significant enhancement of 75% more cell 
killing based on cell viability before and after IRE pulsing was found with addition of 5% 
v/v DMSO in our experimental sets (Figure 2.5, n=4, student t-test, p=0.01). 
 
With pulse timing, the IRE dose, or total energy delivered was similar (51 pulses, 200V, 
and 50μs per pulse), however the total pulses were spread out. Figure 2.5b 
demonstrates that this pulse timing has a dramatic impact and an enhancement of 67% 
in cell killing was achieved. Interestingly, the introduction of time delays also increased 
the time for heat to diffuse, therefore reducing the maximum temperature rise (ΔTmax) 
from 2.7 degrees to less than 1 degree. The time delays were varied for 10s, 30s, 1 min 
and 2 mins, and yielded consistent enhancement results between the baseline IRE and 
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the timing method (student t-test, p=0.008), although no significant difference was 
observed among the different delay times.  After demonstrating that DMSO and delayed 
pulse timing were capable of significant enhancement in vitro, these effects were also 
tested in vivo with a tumor model. 
 
 
Figure 2.5. . In vitro IRE with varied concentrations of DMSO (a) and pulse timing (b). Each data 
point represents the average of n=4 measurements ± SD  
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2.4.2 In Vivo Enhancement: 
In order to demonstrate enhancement in vivo it was again necessary to establish a 
baseline electroporation dose in the DSFC tumor model. This was chosen based on a 
previous IRE study conducted in our lab [101] with the same experimental system. 
Specifically, we chose 50 pulses (500V, 50μs per pulse) as our baseline treatment dose 
as it gives a moderate level of injury of nearly ½ the chamber radius after IRE (10.3 mm3 
by histology and 8.7 mm3 by perfusion defect). 
 
The enhancement results by histology are presented in Figure 2.6, for both DMSO 
treatment and pulse timing. Specifically, Figure 2.6a shows that the tumors treated with 
5% v/v DMSO developed a 24.3 mm3 necrotic lesion compared with the baseline level 
(10.3 mm3) demonstrating a 136% augmentation of volume (p=0.001 from the student t-
test). Similarly, in Figure 2.6c, pulse timing lead to a 20.9 mm3 of necrosis corresponding 
to a 101% increase in volume over baseline (p=0.003 from the student t-test).  
 
No perfusion defect was observed in tumors via intravital imaging before the IRE 
treatment, with or without application of DMSO. Immediately after IRE treatment, the 
blood perfusion was blocked almost across the entire chamber, with or without 
enhancement (Figure 2.6b and 2.6d). This effect has been reported before in [96] and is 
believed to be related to electrical stimulation on the smooth muscle cells, also known as 
the “SMC effect”. In our study, this acute perfusion block is temporal and reversible, as 
revealed by the rapid recovery of perfusion defect by day 1 in all experimental groups.  
At day 1, the perfusion defect stabilized and could be measured. The enhancement 
measured by perfusion defect was similar with that measured by histology. For instance, 
with DMSO addition, the perfusion defect volume was 139% greater than baseline on 
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day 1 and 120% greater on day 3. For the pulse timing method, the perfusion defect 
volume was 111% greater than baseline on day 1 and 109% greater on day 3. The 
perfusion defect radius slightly increases from day 1 to day 3, however, the difference is 
not significant (p>0.15 by student t-test). 
 
 
Figure 2.6. In vivo IRE results with: 5% v/v of DMSO (a) and (b), and pulse timing enhancement 
(c) and (d). Each data point represents the average of n=8 measurements ± SE  
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2.5 Discussion 
A noted limitation of IRE is insufficient treatment volume in tumors. In this work, we 
applied membrane-targeting approaches to increase the treatment volume under similar 
IRE dose (pulse voltage, duration, and number). Specifically, we demonstrated that 
direct application of DMSO at non-toxic concentrations and introducing time delays 
between pulse trains could both increase the destructive potential of IRE. In vitro results 
show 67%~ 75% enhancements in cell killing. Further, in vivo study reproducibly shows 
more than 100% enhancement in the treatment volume by two independent methods 
(p≤0.001 from student t-test). Importantly, we believe that the common mechanism of 
our proposed approaches (DMSO and pulse timing enhancement) is linked to change of 
line tension in the membrane rather than cytotoxicity. This can be argued theoretically 
below for both DMSO and pulse timing. 
 
To demonstrate the impact of decreased line tension on reducing IRE threshold, we 
implemented the nucleation model in [33], [54] with the rate of critical pore formation 
determined by Eqn (2.6): 
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where critical pore energy   ∗is given in Eqn (2.7). 
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57 
The parameters used in our model are summarized in Table 2.2. When a large 
population of cells is exposed to electroporation, the occurrence of irreversible 
membrane breakdown as a result of random fluctuations of pores can be assumed to be 
a stochastic process, with the probability  
 
 
              ∫       
 
 
    (2.8) 
 
We first define    as the threshold of transmembrane voltage which accounts for 
complete membrane breakdown (P>0.99), the impact of line tension   on     can be 
calculated from the above equations. The values of membrane line tension reported in 
literature are 1*10-11 ~6*10-11 J/m [53]. From Figure 2.7a, we can see the reduction of 
membrane line tension has a dramatic impact on IRE threshold. Over one order of 
magnitude of drop in     can be achieved by reducing   from 5*10
-11 to 1*10-11 J/m. In 
our case, the inclusion of 5% v/v DMSO can lower the line tension by at least 20% [149]. 
Therefore, our proposed explanation for DMSO enhancement is that the inclusion of 
DMSO molecules in the cell membrane can lower the edge line tension thus decreasing 
the energy barrier for pore growth, leading to enhanced membrane rupture and cell 
injury after IRE. 
 
Notably the introduction of DMSO also reduces the surface tension of the membrane. 
However, the impact of surface tension on      is marginal compared with line tension as 
shown in the sensitivity curve of    to the membrane surface tension   (Figure 2.7b). 
Specifically, less than 1% drop of    was induced when increase   for one order of 
magnitude (0.1*10-3 to 1*10-3 J/m2), compared to more than one order of magnitude of 
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drop achieved by reducing   for one magnitude. Therefore, the changes of surface 
tension are neglected in our modeling. 
 
 
Figure 2.7. Impact of membrane (a) line tension and (b) surface tension on IRE transmembrane 
threshold. 
 
Similar to DMSO, pulse timing can also be used to directly impact membrane poration by 
reducing line tension in recovering pores. For instance, experimental measurements and 
theoretical estimations of electroporation [46] reveals that under intense electric pulsing, 
membrane defects originates within µs, and can last through the entire time the external 
field is applied (several µs to hundreds of ms). However, the membrane defect recovery 
timing is much slower once the pulsing is finished, generally longer than 1s and can take 
up to minutes [77]. The difference in the two time scales makes it possible to enhance 
the IRE killing effect by fine tuning the pulse timing to leverage these half recovered 
pores.   
 
(a) (b) 
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At least two contribution factors can explain the enhancement effect of pulse timing. 
First, earlier pulses can lead to formation of both reversible and irreversible pores on the 
membrane. Since complete resealing of the membrane can take up to minutes, the cell 
membrane will remain more susceptible to further pulsing due to both reduced 
membrane thickness from recovering pores and reduced line tension [146] during this 
recovery period. Although qualitative calculation is not given here, the dramatic impact of 
reduced line tension has been demonstrated in Eqn (2.6~2.8) and Figure 2.1 and 2.7 
and can help explain the significant enhancement effect from pulse timing. Second, 
extended pore opening time can also increase cell injury and death due to loss of critical 
ions, proteins, and even cell components. When the pulses are delivered in one train, 
only one recovery period is presented after the pulsing. However, when the pulses are 
delivered in several trains with seconds of delays in between, the total pore exposure 
time is the sum of all delays and the final recovery period. Therefore, more secondary 
injury could be caused due to this extended pore opening time. 
 
Importantly, there is the potential for non-uniform DMSO distribution in tissue to affect 
IRE enhancement. In our DSFC model, the local tissue conductivity is assumed to be 
elevated homogeneously as the fluid (saline + DMSO) is added topically and allowed to 
diffuse throughout. We can then argue that the distribution of electric field within the 
tumor should remain relatively constant.  It is however, possible that if the solution were 
injected locally into the tissue, as in a solid tumor case, there could be conductivity 
variations which would change the overall electric field. In addition, testing and 
optimization of the pulse frequency, delay times between pulses, and numbers of pulse 
groups in our pulse timing method are worthy of further study in the future.  
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2.6 Summary 
In this study, two membrane-targeting approaches were shown to increase the treatment 
volume of IRE for local malignant tumors. Specifically, the use of either surfactants (i.e. 
DMSO) or pulse timing to modify membrane properties can greatly enhance IRE 
treatment efficacy. Using the above methods, 67~75% more cell killing in vitro and more 
than 100%  increase in treatment volume in vivo have been achieved without relying on 
any cytotoxic drugs or agents. Because DMSO is commercially available and regularly 
used at low concentrations (<10% v/v), this approach could easily be integrated into 
current IRE procedures to increase the treatment efficacy. In addition, introducing pulse 
timing delays in IRE also increases the destructive potential of IRE without the 
introduction of any foreign agents into the body. Clearly further tests in advanced tumor 
systems (e.g. spontaneous or implanted solid tumors) are needed to more fully evaluate 
the efficacy of our proposed approaches. Nevertheless, we suggest that the simple and 
safe nature of these enhancement approaches compared with cytotoxic drugs may help 
in the refinement of electroporation procedures for cancer. 
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Supplementary Information 
S2.1 DMSO Toxicity Test 
 
Figure S2.1. Toxicity of DMSO on LNCaP cell suspension over time at different concentrations. 
 
S2.2 Calculation of DMSO Diffusion Time in Vivo 
Using unsteady diffusion model in a finite medium: in order to reach a concentration 
63.2% of the topical applied reagents, the diffusion time         6 minutes. L is the 
depth of the point of interest, which is 0.5 mm (the thickness of the DMSO tumor) in our 
case. D is the diffusivity of DMSO in tissue, which is 3*10-6 cm2/s at 23 °C according to 
[150]. 
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Chapter 3. Pulse Timing During Irreversible Electroporation Achieves Enhanced 
Destruction in a Hindlimb Model of Cancer 
 
Contributing Authors: Chunlan Jiang, Qi Shao, and John C. Bischof 
 
The following chapter is in preparation for publication:  
C. Jiang, Q. Shao, and J. C. Bischof, “Pulse Timing During Irreversible Electroporation 
Achieves Enhanced Destruction in a Hindlimb Cancer Model,” Ann Biomed Eng, 2014.  
 
3.1 Introduction 
Irreversible Electroporation (IRE) is an emerging technology that has drawn 
considerable interest in the cancer treatment field. Unlike traditional electroporation, 
where cells are only expected to be temporarily permeabilized and recover after the 
treatment; irreversible, or lethal poration is the goal in cancer therapy applications. 
Although the concept of using IRE as a means of soft tissue destruction was only 
introduced a decade ago [143], abundant pre-clinical testing in vitro [19] and in vivo [21], 
[22], [110] has been undertaken to support this new modality. The purported benefits of 
IRE are that it is simpler and faster while maintaining the minimally invasive nature of 
existing thermal therapies (i.e. RF and cryosurgery) [24]. In addition, it has been 
suggested that IRE could destroy tumor cells while preserving tissue structures such as 
major ducts and vessels within the target region [24]. Being a non-thermal therapy [143], 
[144], IRE is free from the heat sink effect of local vascular system, which helps future 
clinical planning as it is less dependent on perfusion (currently a limiting issue in thermal 
therapies [25], [145]), making IRE a superior candidate for tumors that are adjacent to 
major blood vessels or ducts. A first in-man phase I clinical trial [120] has been 
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conducted on patients with renal cell carcinoma. No significant safety issues were noted 
based on hematological, serum biochemical and ECG recordings of the patients, 
although long-term effects remain to be studied in larger clinical trials. More recent 
clinical trials have been reviewed in [30].  
 
However, despite these encouraging results, there are several limitations with this 
emerging technique, which could present hurdles to its clinical translation. Perhaps the 
most critical one is the inability of IRE to destroy large volumes of tissue under safe 
electric field strengths without repositioning of the probes or repeating treatments. For 
instance, the common lesion sizes reported in the literature with double needle probes 
are currently still small  [26], [29], [57], [110]. 
 
There are several approaches to expand the tissue volume treated by IRE including the 
addition of chemotherapeutic or cytotoxic agents, and approaches that increase 
electropermeabilization of the membrane. Combining chemotherapy with IRE has been 
championed by several groups and is referred to as “electrochemotherapy” [13], [14]. A 
similar method was also proposed recently by Frandsen et al. [61] using direct 
intratumoral calcium injection followed by electroporation, which led to lethal intracellular 
calcium events. While these studies demonstrated improved cell destruction, the focus 
was on enhancing the ability of chemotherapeutic drugs or cytotoxic agents to enter and 
kill the cancer cells rather than enhancing the efficacy of IRE itself. More recently, our 
group has proposed approaches that enhanced the destructive efficacy of IRE itself 
without relying on chemotherapeutic drugs or cytotoxic agents to enter and kill the 
cancer cells [52]. Specifically, mechanisms that directly modify membrane properties 
(i.e. line tension and surface tension, etc.) and improve the impact of pulse timing (which 
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we hypothesize as affecting membrane properties) have been tested and shown 
effective in enhancing the IRE destructive potential. More than 60% increase in cell 
destruction in vitro and greater than 100% increase in treatment volume in a dorsal skin 
fold model have been achieved [52]. However, advanced tumor models (i.e. 3D solid 
tumors) were not used in the previous study.  
 
Therefore, the aim of the present study is to verify that pulse timing enhancement works 
in a 3D tumor model without relying on cytotoxic drugs. For simplicity, enhancement 
protocols with pulse timing were assessed in a human prostate cancer model (LNCaP 
Pro 5) in vivo (hindlimb tumor) on nude mice. The outcome was assessed by relative 
tumor volume reduction and tumor growth delay with or without IRE enhancement. Here, 
we document that the pulse timing approach we propose can be highly effective in 
enhancing the destructive potential of IRE in vivo. We speculate that the mechanism of 
enhancement is linked to reduced membrane stability and extended comprised 
membrane time. 
 
3.2 Materials and Methods 
3.2.1 Tumor Cell Culture and Preparation 
The prostate cancer cell line (LNCaP Pro 5) was cultured as adherent monolayer in 
Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 (BD Biosciences, CA) supplemented 
with 10% fetal bovine serum, 100U/ml of Penicillin/Streptomycin (P4333, Sigma-Aldrich, 
MO), and 10-9 mol/L dihydrotestosterone (DHT) as previously described [52]. When 
>85% confluence was reached, the cells were detached by adding 0.05% Trypsin-EDTA 
(Invitrogen, CA) and then washed twice with serum-free DMEM/F12. Approximately 1-2 
million of the above prepared LNCaP Pro 5 cells were suspended in 100 μL of Matrigel 
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mix (Matrigel, BD Biosciences, San Jose, CA diluted 1:1 in serum-free DMEM/F12 
medium) for one tumor seeding injection.  
 
3.2.2 Animals and Hindlimb Tumor Seeding 
All animal usage and experimental procedure protocols were reviewed and approved by 
the Institutional Animal Care and Use Committee of the University of Minnesota. 6-8 
weeks old nude mice NU/J were obtained from the Jackson Laboratory (Bar Harbor, 
ME). 100 μL of the above prepared Matrigel-cell suspension were injected 
subcutaneously into the hindlimbs of mice under general anesthesia. Experiments were 
performed 4 to 6 weeks after tumor seeding when a tumor diameter of 6 to 8 mm was 
obtained. Animals were randomized into the various groups for experiments. 
 
3.2.3 IRE Setup for Hindlimb Tumor 
The IRE treatment was delivered by a pair of customized needle probes (Figure 3.1) 
connected to an electrical pulse generator (BTX ECM 830, Harvard Apparatus). The 
needles (OD=0.7mm) were fixed on a plastic block with a center to center distance of 
4mm. An insulating layer was coated outside each needle leaving a 3mm tip for 
treatment. For hindlimb tumor treatment, the needle probes were inserted symmetrically 
to the center of the tumor through the skin. In cases when the tumor is not perfectly 
round, the needle plane was aligned with the major axis of the ellipse. Effective 
treatment depth is determined by the exposed needle length (3mm). 
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Figure 3.1. IRE treatment setup and probe design. Bottom (a) and side view (b) of the IRE 
needle probe positioned in the hindlimb tumor. (c) and (d) Photos of the actual IRE probe used. 
 
3.2.4 IRE Treatments  
The IRE and enhancement protocols were designed based on our previous study on the 
enhancement of IRE with pulse timing on cell suspension (in vitro) and dorsal skin fold 
chamber (in vivo) models [52]. IRE parameters and animal grouping can be found in 
Table 3.1. Specifically, 27 tumors were randomly divided into three groups (n=9 each). 
Both baseline and pulse timing groups were given 51 IRE pulses at pulse strengths of 
600 Volts (potential between two probes), durations of 50µs, and frequencies of 10Hz. 
However, for the pulse timing group, the 51 pulses were delivered in 3 trains of 17 
pulses with delays of 30 seconds in between trains. This delivery pattern was 
determined based on our best results from the in vitro experiments suggesting no further 
benefit of longer pulse delays [52]. In addition, the pulse strength (600V) was chosen so 
that the estimate treatment volume is roughly 60% of the total tumor volume (see 
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“Treatment Planning Models” section below), leaving space for the enhancement effect 
to show up. The sham group also received needle penetration with the same set of IRE 
probes, although no IRE or other treatment was delivered.  
 
Table 3.1. IRE parameters and animal grouping 
  N 
Pulse strength 
(Volts) 
Pulse duration 
(μs) 
Pulse number 
Freq. 
(Hz) 
Sham 9 n/a n/a 0 n/a 
IRE  9 600 50 51 10 
Enhancement 9 600 50 51 (3*17 with 30s delays) 10 
 
 
3.2.5 Tumor Growth Delay Assessments 
After IRE treatment, the mice were returned to their cages and monitored for any 
complications. Tumor growth measurements were taken twice a week using a caliper. 
The sizes of the major axis ( ), minor axis ( ), and the thickness ( ) of the tumors were 
measured three times and the averaged values were recorded and used to calculate 
tumor volumes ( ) with Eqn (3.1). All the tumors were monitored for at least 28 days 
after the IRE treatment. 
 
 
  
 
 
        (3.1) 
 
3.2.6 Data Analysis and Statistics 
Group numbers of n≥9 was achieved for the tumor growth delay. The tumor growth 
delay results are presented as average values ± standard deviations. Single factor 
ANOVA tests were performed among the sham and two experimental groups where P 
value ≤ 0.01 was taken to delineate statistical significance among groups. 
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3.3 Treatment Planning Models 
The IRE E-field distributions in the hindlimb tumor were modeled using COMSOL 
Multiphysics software. For our delivery setup shown in Figure 3.1a and 3.1b with 600 
Volts across the two electrodes, the E-field distribution in the hindlimb tumor is 
determined by Laplace equation (Eqn (3.2)): 
 
            (3.2) 
 
where Ω is the electrical conductivity of tumor,   is the electric potential. For 
homogeneous tissue, the electric field calculated from Eqn (3.2) shown in Figure 3.2a. 
The threshold of IRE injury has been experimentally found to be between 
400~1000V/cm [23], [24], [27], [91], [92], [100], depending on the tissue type and 
evaluation method. If we use 600V/cm as a threshold (obtained from our previous study 
using the dorsal skin fold tumor system [101]), the estimated injury region is roughly a 
circle with a radius of 3mm, which corresponds to about 60% of the entire tumor. 
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Figure 3.2. Modeling of IRE in hindlimb tumor: (a) E-field distribution with 600 Volts across the 
two electrodes and (b) end temperature after baseline IRE treatment (51# of 600V, 50µs pulses 
at 10Hz), and (c) end temperature after pulse timing enhancement IRE treatment (3 trains of 17# 
of 600V, 50µs pulses at 10Hz). All figures show the first quadrant of the tumor’s cross section 
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Table 3.2.  Summary of parameters used [52], [78], [143] 
Quantity Symbol Unit Value 
Tissue electrical conductivity Ω S/m 0.286 
Tissue thermal conductivity K W/(m*K) 0.5 
Tissue heat capacity    J/(kg*K) 3750 
Tissue density ρ kg/m
3 
1000 
Blood temperature Tb C 37 
Blood density    kg/m
3 
1000 
Blood heat capacity    J/(kg*K) 3640 
Blood perfusion rate    kg/(m
3
*s) 0.5 
Metabolic heat      W/m
3 
16900 
Heat transfer coefficient h W/(m
2
*K) 50 
Initial tumor temperature T0 C 37 
Room temperature Tr C 25 
IRE electric potential   volt 600 
IRE pulse duration td us 50 
IRE total pulse number N n/a 50 
IRE frequency f Hz 10 
Free energy with pore formation    J  
Pore radius R m  
Transmembrane voltage U Volt  
Membrane line tension   J/m 1~6*10
-11
 
Membrane surface tension   J/m
2 
0.5~2*10
-3
 
Lipid-water dielectric coefficient   n/a 0.043 
Charging time constant    1/s  
Membrane thickness   m 10*10
-9
 
Specific membrane capacitance     μF/cm
2 
0.95 
Specific intracellular conductivities      mS/cm 4.55 
Specific extracellular conductivities    mS/cm
 
50 
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When neglecting heat losses, the energy from electric current all goes to tissue heating, 
which is illustrated by: 
 
       |  |  (3.3) 
 
Using the bioheat equation implemented in COMSOL by adding a heating term (SAR in 
Eqn (3.4)) from the electric pulsing: 
 
 
   
  
  
                          
        (3.4) 
 
where  ,   , and   are density, heat capacity and temperature of the tissue,    ,      , 
and    are density, flow rate, heat capacity and temperature of the blood, and  
    is 
metabolic heat. The parameters used in our models are summarized in Table 3.2. This 
model allows the temperature rise after IRE pulsing to be captured as shown in Figure 
3.2b and 3.2c. Based on our simulation results, the maximum temperature rise is found 
next to the inner side of the electrodes, and is less than 43 degrees Celsius (Figure 
3.2b) for a continuous delivery of 51 pulses for parameters shown in Table 3.1. Even for 
the worst case scenario case in which the tissue is kept at 43 degrees Celsius for the 
entire treatment period (5 seconds), the thermal dose is still far too low to cause thermal 
injury according to the CEM43 (cumulative equivalent minutes at 43 degrees Celsius) 
method [151]. For the enhancement method (see pulse timing in Table 3.1), the 
temperature rise is even less (about 41 degrees Celsius, Figure 3.2c) because more 
heat has dissipated during the two delay periods. It is worth noting that the conductivity 
of tissue will increase during IRE due to electroporation’s permeabilization effect which 
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has been noted in previous work from our lab [101] and others [85], [99]. We have 
elected not to pursue this here in order to focus solely on the impact of pulse timing 
without the confounding effects of conductivity change. Certainly more careful study is 
warranted in the future. 
 
3.4 Results 
3.4.1 Animal Response 
All the animals in the treated groups (with or without enhancement) survived the 
procedure. Upon application of the IRE pulses, a mild to moderate level of generalized 
muscle contraction occurred in each animal. This effect has been noticed and reported 
in many in vivo studies [24], [25]. It has been reported that when Pancuronium is 
administered to the animals the contractions are manageable even when a maximal 
voltage of 3kV was applied [24], although this was not used in this study. A mild swelling 
was also observed on each IRE treated tumor (with or without enhancement) for about 
24 hours after treatment, but not on sham tumors. By 48 hours after IRE, all the swelling 
conditions were gone and the needle penetration sites were hardly noticeable. No other 
complications were observed in our experiments. 
 
3.4.2 Tumor Growth Evaluation 
The average tumor size before IRE treatment in our experiments was 96mm3 from Eqn 
(3.1), with L=8.89±0.22mm, S=6.99±0.11mm, and H=2.97±0.09mm. After treatment, 
each tumor’s volume was monitored for 30 days and compared to the initial volume. The 
relative growth delays are shown in Figure 3.3 and Table 3.3. Specifically, tumors 
treated with either baseline IRE or pulse timing enhanced IRE exhibited reductions in 
tumor volumes compared to the shams. Baseline IRE treatment lead to a 26% to 30% 
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tumor destruction compared to sham over the course of study. This contrasts with the 
pulse timing enhancement group, which showed 54% to 62% tumor destruction 
compared to sham. This suggests that a consistent enhancement of more than 33% 
over baseline IRE up to the 28 days in our study. Furthermore, it took 1 week for the 
baseline IRE treated tumors to grow back to their original sizes, compared to 3 weeks for 
the pulse timing enhancement group. In other words, the pulse timing enhancement 
approach demonstrated 2 additional weeks of tumor growth delay compared to the 
baseline IRE. Also, only pulse timing enhanced IRE was able to achieve complete tumor 
regression with our experiment setup and chosen parameters. 
  
Using single factor ANOVA test, the above differences in tumor volume measurements 
are statistically significant, with a p value of 0.0065. 
 
Table 3.3.  Relative tumor volume reduction with various treatments 
 
Day 0 7 14 21 28 
Sham Relative size 1 1.269 1.835 2.393 2.829 
IRE Relative size 1 0.898 1.358 1.764 1.965 
 
Reduction compared to 
Sham  
29.19% 26.01% 26.28% 30.54% 
Enhancement Relative size 1 0.553 0.706 1.046 1.302 
 
Reduction compared to 
Sham  
56.44% 61.52% 56.27% 53.99% 
  
Reduction compared to 
IRE 
  38.48% 47.99% 40.67% 33.76% 
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Figure 3.3. Injury response of pulse timing enhanced IRE treatment in the LNCaP hindlimb tumor 
model. (a) Normalized tumor sizes over 28 days after IRE treatment.  Each data point represents 
the average of n=9 measurements ± SE. (b) Tumor response at day 28 after IRE for various 
treatments. Volume=0 represents no palpable tumor on the overlying skin 
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3.5 Discussion 
This work is an extension of our previous study on membrane targeting approaches to 
enhance IRE. Specifically, in the previous study we demonstrated significant 
enhancement (67–75% more cell destruction in vitro and >100% increase in treatment 
volume in an intravital dorsal skin fold chamber tumor model) can be achieved with 
direct application of DMSO at non-toxic concentrations and through pulse timing (i.e. 
introducing time delays between pulse trains) [52]. In the current study, we are able to 
verify the enhancement effect of the pulse timing approach in an solid 3D tumor model in 
vivo, and demonstrated 2 weeks longer of tumor growth delay compared to baseline IRE 
treatment. The results from our different models are compared and summarized in Table 
3.4. 
 
Table 3.4. Summary of IRE enhancement results  
Model Approach Outcome Ref. 
In Vitro  
(Cell 
suspension) 
Baseline IRE Baseline cell destruction (~50%) 
[52] DMSO 75% increase over baseline 
Timing 67% increase over baseline 
In Vivo 2D 
Tumor  
(DSFC) 
Baseline IRE Baseline histological destruction (10.3mm
3
) 
[52] DMSO 136% increase over baseline 
Timing 101% increase over baseline 
In Vivo 3D 
Tumor 
(Hindlimb) 
Baseline IRE Baseline tumor growth delay (1 week) This 
study 
Timing 200% increase over baseline 
 
In addition to experimental verifications, we would like to further explore the possible 
mechanisms of the pulse timing enhancement approach. The energy based nucleation 
model and influences of modifying the membrane properties (i.e. line tension and 
surface tension) on the outcome of IRE treatment have been discussed in our previous 
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study [52]. Our proposed explanation for DMSO enhancement is that the inclusion of 
DMSO molecules in the cell membrane can lower the edge line tension thus decreasing 
the energy barrier for pore growth, leading to enhanced membrane rupture and cell 
injury after IRE. To understand the mechanism of pulse timing enhancement, it is worth 
discussing the time frames of IRE (Figure 3.4). The generation of transmembrane 
potential around the cells depends on ion concentration of the surrounding medium, but 
is in the range of micro-seconds [31], [56], [77], [78] from modeling. Take a single cell 
(  50µs) as an example, the membrane charging time constant (  ) can be determined 
by Eqn(3.5) [34], [46]: 
 
 
         
 
  
 
 
   
  (3.5) 
 
in which    is the specific membrane capacitance,    and    are intracellular and 
extracellular specific conductivities. With the typical values used in Table 3.2, the 
charging time is estimated to be 1.1 µs. Compared to the pulse duration (50 µs), 
intervals (100ms), and time delay between pulse trains (30s) (Figure 3.4), this charging 
time can be neglected. Membrane defects usually originates within µs, and can last 
through the entire time the external field is applied (several µs to hundreds of ms) [82], 
[86]. However, the membrane defect recovery timing (if reversible) is much slower once 
the pulsing is finished, generally longer than 1s and can take up to minutes. The 
difference in the two time scales makes it possible to enhance the IRE killing effect by 
fine tuning the pulse timing to leverage these half recovered pores.  
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Figure 3.4. Illustration of the time frames of reversible membrane defects created by IRE pulses. 
 
At least two contributing factors can explain the enhancement effect of pulse timing. 
First, similar to DMSO, pulse timing can also directly impact membrane poration by 
reducing line tension in recovering pores. Earlier pulses can lead to formation of both 
reversible and irreversible pores on the membrane. Since complete resealing of the 
membrane can take up to minutes, the cell membrane will remain more susceptible to 
further pulsing due to both reduced membrane thickness from recovering pores and 
reduced line tension [146] during this recovery period. Although qualitative calculation is 
not given here, the dramatic impact of reduced line tension has been demonstrated in 
[52] and can help explain the significant enhancement effect from pulse timing. Second, 
extended pore opening time can also increase cell injury and death due to loss of critical 
ions, proteins, and even cell components. When the pulses are delivered in one train, 
only one recovery period is presented after the pulsing. However, when the pulses are 
delivered in several trains with seconds of delays in between, the total pore exposure 
time is the sum of all delays and the final recovery period. Therefore, more secondary 
injury could be caused due to this extended pore opening time. 
 
Lastly, it is of great interest to explore what other pulse timing delivery patterns can 
provide enhancement to IRE, and whether there is an optimum delivery pattern. The 30 
seconds delay in our proposed approach was selected based on our previous study 
78 
[136] which showed that other delay periods (10s, 1min, and 2mins) yield equivalent or 
less benefit in our experiment setup. However, the range we studied was limited and 
further testing on other delay period selections are still needed to fully characterize the 
potential of the pulse timing approach. Similarly, in our study the pulses were divided 
into three trains, but other or better possibilities may exist. It may also be helpful to 
develop a model to characterize the effect of pulse timing. To achieve that, a better 
understanding of the pore recovery time frame and IRE injury mechanism is highly 
needed. Finally, it should be noted that these enhancement results were generated on 
one cell and tissue system (LNCaP Pro 5 prostate cancer). While we believe that the 
enhancement mechanisms will hold in other systems, the precise parameters leading to 
this enhancement are expected to be system (i.e. particularly membrane) specific. 
 
3.6 Summary 
In this study, a pulse timing approach has been used to increase tumor destruction of 
IRE treatment and thereby delay tumor growth for local hindlimb tumors in mice. Using 
our experiment setup, more than 33% additional tumor destruction and 2 weeks longer 
tumor growth delay have been achieved compared to baseline IRE treatment without 
relying on any cytotoxic drugs or agents. Because the pulse timing approach does not 
introduce any foreign agents into the body, it could easily be integrated into current IRE 
procedures to increase the treatment efficacy. Further opportunities exist in optimizing 
the pulse timing delivery approach and understanding the fundamental mechanisms. 
Nevertheless, we suggest that the simple and safe nature of the pulse timing approach 
compared with cytotoxic drugs may help to translate this approach into the clinic. 
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Chapter 4. Irreversible Electroporation for Non-Cancer Targets 
 
Contributing Authors: Chunlan Jiang, Ryan Goff, Pong Patana-anake, Paul A. Iaizzo, 
and John C. Bischof 
 
The following chapter appeared in publications:  
C. Jiang, R. Goff, P. Patana, P. A. Iaizzo, and J. C. Bischof, “Irreversible electroporation 
of cardiovascular cells and tissues,” J. Med. Devices., 7(3), 2013. 
 
C. Jiang, P. Patana, and J. C. Bischof, “Neural Cells Show Higher Sensitivity to 
Irreversible Electroporation Compared to Cancer and Cardiovascular Cells”, presented 
at the ASME Design of Medical Device Conference, April, 2014. 
 
4.1 Introduction 
Since Davalos, Rubinsky, and Mir [16] proposed the use of electroporation as a means 
of soft tissue destruction, numerous pre-clinical in vitro [19] and in vivo [21], [22], [110] 
testing have been undertaken to investigate its therapeutic values in cancer treatment, 
but far less effort has been given to other disease targets. For example, a wide variety of 
cell [17]–[20], [57], [68], organ [26]–[28], and animal [21], [24], [29] models have been 
used to characterize IRE in different cancer types, as reviewed in Table 1.2. A first in-
man phase I clinical trial [120] has also been conducted on patients with renal cell 
carcinoma in 2010, only 7 years after the concept of IRE therapy was first introduced. 
Currently, large scale, multi-center clinical trials are being carried out around the world 
on IRE cancer therapy (Table 1.3, Figure 1.9). However, compared to the rapid 
development of IRE application on treating cancers, much less progress has been made 
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on other disease types, such as cardiovascular diseases [105], [107] and neural 
disorders [62], [152], [153]. Therefore, this chapter is dedicated to explore the potential 
applications of IRE therapy for cardiovascular, neural, and other non-cancer targets. 
 
4.2 IRE of Cardiovascular Cells and Tissues 
4.2.1 Background 
Cardiovascular disease remains the number one cause of death in the United States 
and in 2010 was responsible for 17% of the US health expenditures ($272.5 billion) 
[154]. Many acquired cardiovascular diseases are associated with abnormal proliferation 
of vascular smooth muscle cells (e.g. heart attack) or irregular electrical pathways (e.g. 
arrhythmia). Of the various methods applied to manage cardiovascular diseases, using 
energy-based technologies to create myocardial lesions (i.e. “ablation”) has gained 
increasing popularities due to their effectiveness, short treatment times, and minimal 
surgical damages.      
 
Radiofrequency (RF) energy was one of the earliest technologies used for catheter 
ablation and currently has the greatest patient-year experience [155]. It should be noted 
that several other thermal technologies, such as high-intensity focused ultrasound 
(HIFU), catheter-based cryo, focused laser, and microwaves, have also been proposed 
as potential sources for cardiovascular ablation. However, to date, each of these 
sources relies on direct diffusion of energy, which can take significant time and increase 
risks for collateral damage to surrounding structures. 
 
Irreversible Electroporation (IRE), on the other hand, is an emerging technology that 
may also provide new opportunities for treatments of cardiovascular diseases. Unlike 
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thermal technologies, IRE is based on the electrical field distribution rather than 
diffusion, and induces cell death by increasing permeabilities, thus leaving long-term 
defects within cell membranes [1]. Because IRE does not rely on heating or cooling to 
create lesions, it also benefits from reduced interaction with blood flow: a distinct 
disadvantage of thermal ablative techniques within the heart or near large vessels.  
 
In this report, we evaluated the abilities of IRE to destroy both cardiovascular cells and 
tissues, as a first step to better understand threshold and use in his new area. To do so, 
we use a cardiac muscle cell line (HL-1[156]) in order to characterize the biophysical 
effects and thresholds of IRE on cardiovascular cells. Next, we applied direct IRE 
therapy on isolated pulmonary vein tissues: i.e., to investigate treatment efficacies in 
vitro. Specific influences of IRE applied therapeutic variables (E-field, pulse duration and 
number) were studied and compared based on the elicitation of injury (i.e., cell 
membrane integrity and cellular dehydrogenase activity). These results may aid in 
designing more effective approaches to treat cardiovascular diseases using IRE. 
 
4.2.2 Materials and Methods 
4.2.2.1 Cardiac muscle cell cultures 
A HL-1 cell line was cultured as adherent monolayers [156]. More specifically, cells were 
grown in T-75 flasks with Claycomb medium (51800C, Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum, 2mM L-Glutamine, 100U/ml of 
Penicillin/Streptomycin, and 0.1mM Norepinephrine. When 90% confluence was reached 
and spontaneous beating was elicited (observed under the microscope), the cells were 
detached by adding 0.05% Trypsin-EDTA (Invitrogen, CA) and then formed into a single 
cell suspension. 
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4.2.2.2 Electroporation and viability assays of HL-1 cell line 
400μl volumes of the prepared HL-1 suspensions (0.5~0.6 million cells/ml) were pipetted 
into electroporation cuvettes (Fisher Scientific), which were then placed in an external 
electrical field created by an electrical pulse generator (BTX ECM 830, Harvard 
Apparatus) as shown in Figure 4.1a. The output voltages and currents were monitored 
by an oscilloscope (Tektronix TDS 2002). After electroporation, 100μl aliquots of treated 
cell suspensions were transferred from the cuvette to micro centrifuge tubes and 
incubated with Hoechst 33342 (10μM) and Propidium iodide (PI) dyes (7.5μM) for 
15mins. These samples were then observed under a fluorescent microscope and photos 
were taken to calculate relative cell viabilities. 
 
 
 
             
 
 
Figure 4.1. Electroporation experiment setups for cardiovascular cells and PV tissue: (a) cell 
suspensions within a cuvette placed in an external electrical field, and (b) treatment of a vascular 
tissue with ring-needle electrode configuration  
 
Porcine pulmonary vein tissue preparations: Lungs were harvested immediately post-
mortem from Yorkshire-cross swine: those being used for other IACUC approved 
(a) (b) 
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studies. The pulmonary veins (PV) distal to the heart were identified and dissected from 
the lung using blunt dissection techniques. The PVs were washed in Krebs-Henseleit 
buffer and cut along an axial direction. The PV biopsies were then laid flat in a 5cm petri 
dish with the endothelial surfaces facing upward. The elastomer formed bottoms of the 
petri dishes facilitate fixation of the tissue and proper electrode positioning (see Figure 
4.1b).  
  
4.2.2.3 Electroporation and injury characterization of the pulmonary tissues 
After removal of the Krebs-Henseleit buffer, a ring electrode (cathode) was placed on the 
tissue surface with a needle electrode (anode) inserted from the center of the ring. The 
diameters of the ring (inner) and needle electrode were 8mm and 1mm, respectively. 
After the applied electroporation, each sample was again immersed with the Krebs-
Henseleit buffer and incubated for 3 hours followed by staining with 1% Triphenyl 
tetrazolium chloride (TTC assay) in Trizma buffer (Sigma-Aldrich, St. Louis, MO) for 1 
hour. Photos were taken on the stained samples so to measure the relative necrosis 
areas. 
 
4.2.3 Results 
4.2.3.1 Cardiac muscle cell model 
The initial electroporation parameters were chosen based on our previous experience 
with a cell line [52]. We fixed the applied pulses at a voltage of 200V (inducing an 
external electrical filed of 1000V/cm over the 2mm cuvette gap), and tested 
electroporation treatments consisting of 10, 50, and 99 pulses with 50µs pulse duration 
and 10Hz frequency. The cell viability after electroporation was evaluated using the dye-
staining assay and obtained results are shown in Figure 4.2.  
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Figure 4.2. Viability results of the HL-1 cell line after electroporation with 200V, 50μs, 10Hz, and 
varied number of pulses. (N=4, error bars represent standard deviations.) 
 
The resultant viability data (Figure 4.2) indicated that IRE can indeed cause damage of 
cardiac muscle cells within our experimental setup. The moderate injury level (i.e. 
viability) was induced with a set of 50 pulses of 200V, 50µs durations at 10Hz: i.e., of 
approximately 43%.  As the treatment doses increased (pulse number in this case), the 
injury level increased accordingly. When compared with results from cancer cell line [52], 
the injury levels of HL-1 were higher under the same treatment conditions, which may 
indicate that the HL-1 cells are more susceptible to IRE injury. 
 
4.2.3.2. Pulmonary vein tissue model 
For the PV ablation, we applied 500V on the center electrode and grounded the ring 
electrode, which creates an attenuating electrical field over a radial direction within the 
ring area (Figure 4.4). The creation of such electrical fields helped identify treatment 
thresholds: i.e., when comparing the electrical field distributions with resultant lesion 
sizes. A total of 50 pulses with 50µs duration and 10Hz frequency were delivered for 
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these treatments. A set of photos demonstrating the staining effect of control and treated 
samples are shown below in Figure 4.3.  
 
           
 
Figure 4.3. Relative injuries of PV tissues as determined by TTC staining: (a) control and (b) after 
IRE treatment  
 
For the PV ablation system, the electric field distribution within the ring electrode can be 
calculated from the Laplace equation (Eqn 4.1), as was demonstrated in Figure 4.4.  
 
            (4.1) 
 
The lesion size (measured as radius from the center electrode to the edge of lesion) 
induced by such therapy was 1.95 mm (n=3, with a standard deviation of 0.07 mm), 
which corresponds to an electric field strength of 1200V/cm.   
1mm 1mm 
(a) (b) 
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Figure 4.4. Relative electrical field distributions as a function of radial distances from the center 
electrode versus the effects on the IRE treated PV samples 
 
 
4.2.4 Summary 
This preliminary work supports the idea that IRE can be used for creating lesions in 
patients with cardiovascular diseases. For example, effective injury was achieved with 
electric field strength of 1000V/cm for isolated cardiac muscle cells, and 1200V/cm for 
PVs.  
 
4.3 Irreversible Electroporation of Neural Cells  
4.3.1 Background 
In 2012, around one billion people worldwide were suffering from neurological disorders 
such as epilepsy, incontinence, chronic and arthritis pain, which significantly affect the 
patient’s quality of life. These disorders are associated with biochemical or electrical 
abnormalities of the central and peripheral nervous system (brain, spinal cord, 
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autonomous nervous system, etc.). Although many of these disorders can be controlled 
or mitigated by drugs, the efficacy and long term side effects of drugs are limiting their 
acceptance. More recently, energy-based focal therapies (e.g. Radiofrequency) have 
been used for neural ablation. For instance, studies have shown that ablation can 
effectively help treat chronic pain (joint [157], back, sciatica [158], etc). Radiofrequency 
ablation applied to renal arteries resulted in a substantial and sustained reduction in 
blood pressure without apparent procedural or subsequent biochemical complications 
[157], [159]. In addition, research on using cryoablation on the pulmonary vein to 
manage atrial fibrillation is also underway [160], [161]. 
  
Irreversible Electroporation (IRE), an emerging technology that has attracted much 
interest and lead to numerous studies in cancer therapy, may also provide new 
opportunities for treatment of neural disorders. Unlike thermal technologies, IRE is 
based on the electric field (E-field) distribution rather than heat diffusion, and induces 
cell death by increasing permeability [1]. Because IRE does not rely on heating or 
cooling to create lesions, it also benefits from increased speed and reduced interaction 
with blood flow: a distinct disadvantage of thermal ablative techniques in and around 
large blood vessels.   
  
In this report, we evaluated the ability of IRE to destroy neural cells to understand 
potential therapeutic value in treating neural disorders. To do so, we used an adult male 
mouse hypothalamic cell line (CLU-172 [162]) to characterize the biophysical effects and 
injury thresholds of IRE on neural cells. Specific influences of IRE therapeutic variables 
(E-field, pulse number and duration) were studied and compared based on the elicitation 
of injury (i.e., dehydrogenase activity). Further, a direct comparison of these results with 
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those from cancer (LNCaP Pro5) and cardiovascular (HL-1) cell lines demonstrates a 
higher sensitivity of neural cells to IRE than other cell types. These results will aid in 
exploring the potential of IRE to treat neural disorders and selection of appropriate IRE 
therapeutic variables.     
 
4.3.2 Materials and Methods 
4.3.2.1 Neural cell culture 
The CLU-172 cell line was cultured as adherent monolayers as described in [162]. More 
specifically, cells were grown in T-75 flasks with high glucose DMEM medium (D5796, 
Sigma-Aldrich, MO) supplemented with 10% fetal bovine serum, 100U/ml of 
Penicillin/Streptomycin/Neomycin (15070-063, Invitrogen, CA). When 90% confluence 
was reached, the cells were detached by adding 0.05% Trypsin-EDTA (Invitrogen, CA) 
and then formed into a single cell suspension.  
 
4.3.2.2 Cardiac muscle cell cultures  
The cell culture procedure of the HL-1 cell line is similar to above with slight changes: 
the cells culture medium was made with Claycomb medium (51800C, Sigma-Aldrich, 
MO) supplemented with 10% fetal bovine serum, 2mM L-Glutamine, 100U/ml of 
Pen/Strep, and 0.1mM Norepinephrine. 
 
4.3.2.3 Cancer cell culture  
The culture procedure of the LNCaP Pro 5 cell line has been detailed in [52]. 
 
4.3.2.4 Electroporation Treatment  
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400μl volumes of the prepared cell suspensions (0.5~0.6 million cells/ml) were pipetted 
into electroporation cuvettes (Fisher Scientific) which were then placed in an 
homogeneous external electrical field created by an electrical pulse generator (BTX 
ECM 830, Harvard Apparatus). The output voltages and currents were monitored by an 
oscilloscope (Tektronix TDS 2002). 
 
4.3.2.5 Injury Evaluations  
The viability of neural and cancer cell lines were evaluated using a Tetrazolium-based 
CCK-8 assay (Dojindo Molecular Technologies, Inc) that measures the dehydrogenase 
enzymatic activity associated with metabolic processes in live cells. After IRE, 100 μl 
aliquots of the cell suspensions were mixed with 10 μl of CCK-8 reagent in a 96 well 
plate then incubated for 4 hours at 37 oC with 5% CO2. The optical absorption of the 
sample was then read in a spectrophotometer (Synergy, BioTek Inc.) at a wavelength of 
450 nm to determine the viability according to a standard protocol in the manufacturer’s 
manual. The viability results of the HL-1 cell line were evaluated using membrane dye 
assay because of the interference of the HL-1 cell culture medium with the CCK-8 
reagent. After electroporation, 100μl aliquots of treated cell suspensions were 
transferred from the cuvette to micro centrifuge tubes and incubated with Hoechst 33342 
(10μM) and Propidium iodide (PI) dyes (7.5μM) for 15 minutes. These samples were 
then examined under a fluorescent microscope and photos were taken to calculate 
relative cell viabilities. 
 
4.3.3 Results 
All three IRE therapeutic variables (E-field, pulse number and duration) studied in our 
experiments were influential on the outcome of neural cell destruction, although we 
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found E-field to be the most critical factor (Figure 4.5). Specifically, for IRE to induce 
initial cell injury (more than 5% cell death), the E-field needs to be greater than 750V/cm, 
while to achieve complete cell destruction (more than 95% cell death), the E-field 
required in our experiment setup is 1000V/cm with 99 of 50μs long pulses.  
  
 
 
 
Figure 4.5. In vitro IRE treatment on CLU-172 cells with various E-field strengths and (a) 10, 50, 
and 99 pulse number with 50μs duration or (b) 10 μs, 50μs, or 100 μs duration with 50 pulse 
number. Pulse frequency is 10Hz for each case. N=3, error bars represent standard deviations 
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Both pulse number and pulse duration have significant impact on E-field thresholds. With 
50μs long pulses (figure 4.5a), the E-field threshold for complete cell destruction 
increased to 1250V/cm for 50 pulses and to 2000V/cm for 10 pulses. With 50 pulses 
(figure 4.5b), the E-field thresholds for complete cell destruction are 1250V/cm, 
1250V/cm, and 1750V/cm for 10 μs, 50 μs, and 100 μs long pulses, respectively. 
 
The resultant viability data (Figure 4.5) indicated that IRE can indeed cause various 
levels of damage of the neural cells within our experimental design. The fact that 
increasing pulse number or duration can lower the E-field threshold is strongly 
suggesting a “treatment dosage” role of the pulse number and duration in IRE.  
  
It is also interesting to compare the outcome of IRE therapy on neural cells with that of 
the cardiovascular and cancer cell lines from the same experiment model (Figure 4.6). 
The initial injury thresholds for all three cell lines are similar (around 750V/cm). However, 
the E-field threshold for complete cell destruction is the lowest for neural cells and 
highest for cancer cells. This observation suggests that neural cells are more sensitive to 
injurious IRE pulses, and have a narrower transition zone from complete live to complete 
dead. Such cell line specific difference can also potentially help design treatment 
protocols in which neural cells are selectively killed within the same target region where 
other types of cells (e.g. cardiac muscle cells) are present.  
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Figure 4.6. In vitro IRE treatments on cancer (LNCaP Pro5), Cardiovascular (HL-1) and neural 
(CLU-172) cells with various E-field strength and 50 of 50μs pulses at 10Hz 
  
4.3.4 Summary 
Although further experiments are needed to confirm these findings, our preliminary 
results support the idea that IRE can be used to preferentially deactivate nerves in 
patients with neural disorders. Effective injury can be achieved with appropriate 
combination of E-field strength, pulse number and pulse duration. Further 
characterization and testing of other IRE parameters and on advanced neural models 
will be needed to fully translate this finding. 
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Chapter 5. Future Directions 
 
5.1 IRE Mechanisms 
IRE therapy has been used in both pre-clinical and clinical environments for almost a 
decade (Table 1.2 and 1.3). Although many encouraging results have been reported and 
unique benefits have been observed compared to other focal therapies (See Chapter 1), 
several essential aspects of IRE mechanisms are still lacking.  
 
For instance, the principle effect that defines IRE is the irreversible change of membrane 
permeability. However, the connection between permeability change and cell injury is 
still unclear. In our previous sessions (1.2 and 1.3.1.3), two classes of injury 
mechanisms have been introduced at the cellular level: direct irreversible membrane 
defect and secondary cellular responses. To model the irreversible membrane defect, a 
nucleation based energy model (Eqn 1.3) has been used and supported by the majority 
of people in the field [51], [54]. The secondary cell injury effects are more complicated 
and difficult to model. Several different processes could contribute to the secondary cell 
injuries, including protein denaturation [34], osmotic imbalance, flush in/out of ions, 
depletion of ATP [61], or uptake of toxic/foreign molecules [14], etc. The questions 
whether these secondary effects contribute to the final cell death and how to model 
these effects are ongoing areas of study. 
 
The IRE injury mechanism in the tissue environment in vivo is even more complicated 
because of the live organism’s response to injury as a system. Only a limited number of 
studies have investigated the living body’s systematic response to IRE, and the 
conclusions are contradictive. Al-Sakere et. al. [98] reported that IRE does not induce an 
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infiltration of immune cells to the tumor because of the destruction of infiltration routes, 
therefore the immune response is not instrumental in IRE efficacy. In contrast, Onik et. 
al. [25] observed a significant immunologic reaction in the lymph nodes draining the 
treatment area. Li et. al. [152] also reported that IRE modified the cellular immune 
response compared with surgical resection.  
 
 
 
Figure 5.1. IRE on rat artery after 28 days (H&E X100 magnification). Top picture shows a 
normal right common carotid artery. Bottom picture shows a left common carotid artery 28 days 
after irreversible electroporation. There are almost no vascular smooth muscle cells in the tunica 
media, compared with control artery. The thickness of the tunica media is reduced. There is no 
neointimal formation. There is marked fibrosis and hypercellularity in the adventitia layer of the 
IRE artery, compared with the control. (A, intraarterial lumen; B, tunica media; C, tunica 
adventitia; **, area of fibrosis and hypercellularity). [105] Published with permission from: “The 
effect of irreversible electroporation on blood vessels,” Technol. Cancer Res. Treat., vol. 6, no. 4, 
pp. 307–312, Aug. 2007, Adeninepress, http://www.tcrt.org. 
 
In addition, the impact of IRE on the vasculature system requires further study in vivo. 
One of the major claimed benefits of IRE is its ability to spare major blood vessels and 
ducts within the treatment zone [24]. However, while the vessel structure may remain, 
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the cells will often be injured. In fact, studies on direct IRE application on blood vessels 
have shown that IRE kills most of the cells to the margin of the blood vessel including 
the vascular smooth muscle cells (Figure 5.1) [105]. What IRE apparently does not 
compromise are the internal lamina and endothelial layers. Importantly, an intact 
endothelial layer is essential for the physiological function of blood vessels. This 
selective killing effect of IRE may explain why the blood vessel matrix is preserved after 
IRE [105].  
 
5.2 IRE Treatment Planning 
Currently, the most popular approach researchers use to predict treatment outcome in 
pre-clinical and clinical IRE is predicting the distribution of electric field within the tissue 
and comparing it with an electric field threshold obtained either from modeling or 
previous experience (Table 1.2). However, several critical factors need to be considered 
with this treatment planning method. 
 
Firstly, it has been widely recognized that different cell types respond differently to IRE 
injury. For instance, Bao et. al. [18] treated lung cancer, red blood cells, and white blood 
cells using the same IRE system, and found the threshold for red blood cells 
(1100~1200V/cm) to be significantly higher than lung cancer (300~400V/cm) and white 
blood cells (400~500V/cm). Maor et. al. also found that when IRE is directly applied to 
the rate artery, the number of vascular smooth muscle cells is significantly reduced while 
endothelial cells are mostly preserved [105]. Further, we compared the responses of 
cancer, cardiovascular, and neural cells to IRE treatment (Chapter 4.3), and found that 
neural cells have a lower threshold for IRE destruction compared to the other two cell 
lines (Figure 4.6). It is thus of great interest to investigate what properties of the different 
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cell types contribute to their differences in IRE response. And more importantly, it is 
necessary to characterize the specific IRE thresholds when performing treatment 
planning for different therapeutic targets. 
 
In addition, the heterogeneity of injury response within the target treatment zone also 
needs to be considered. It is now becoming appreciated with a few studies [29], [101] 
that incomplete treatment (live tumor patches in a target treated zone) have been found 
after IRE. This phenomenon is a real concern for cancer treatments due to the likelihood 
of recurrence, and if unresolved, represents a threat to the eventual translation of IRE. 
Having studied pre-clinical lesions for IRE, heat and cryo in an identical animal model, 
the appearance of live tumor patches within the treated tumor volume (rather than at the 
boundary) appears to be unique for electroporation (although more work is needed) 
[101], [133]. It is possible that the live cell patches are a result of local electrical property 
heterogeneity within the tumor tissue thereby lowering the effective electric field in the 
target region [134]. Thus, methods that can ensure the electric field distribution over the 
entire target region is above the IRE threshold is needed to improve the reliability of IRE 
cancer therapy. 
 
Another topic in IRE treatment planning is the influence of pulse duration and pulse 
number on the outcome of IRE. It has been shown in our (Figure 1.6) and other studies 
[17], [31] that when electric field is kept the same, viability after IRE treatment can vary 
depending on the pulse duration and number delivered. The influences of pulse duration 
and pulse timing are similar to the “thermal dose” concept in thermal therapies (i.e. 
radiofrequency [151]). Therefore, it is important for people to report the pulse duration 
and pulse number used along with the electric field when determining the threshold for 
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treating a specific type of tissue. And careful consideration needs to be given to the 
pulse duration and number during treatment planning. 
 
5.3 Enhancement Potentials 
The two IRE enhancement approaches we proposed in Chapter 2 and 3, directly DMSO 
application and change of pulse timing, have both demonstrated significant cell 
destruction enhancement effect in various cancer models in vitro (cell suspension) and 
in vivo (DSFC and hindlimb tumors). However, our results are still limited in terms of 
experiment parameter range and the following future work is proposed as useful. 
 
5.3.1 Adjuvant Delivery (DMSO) 
The challenge of drug delivery in tumor has long been recognized in cancer treatment, 
and is a main motivation for people to introduce electroporation to chemo therapy [8], [9], 
[13]. There is the potential for non-uniform DMSO distribution in tissue to affect IRE 
enhancement. In our DSFC model, the local tissue conductivity is assumed to be 
elevated homogeneously as the fluid (saline + DMSO) is added topically and allowed to 
diffuse throughout a relatively thin tumor layer (0.5mm). We can then argue that the 
distribution of electric field within the tumor should remain relatively constant. It is, 
however, highly possible that if the solution were injected locally into the tissue, as in a 
solid tumor case, there could be conductivity variations that would change the overall 
electric field distribution. This could add to the risk of incomplete treatment and local 
occurrence in clinical applications. 
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5.3.2 Pulse Timing Optimization 
It is also interesting to explore what other pulse timing delivery patterns can provide 
enhancement to IRE, and whether there is an optimum delivery pattern. The 30 seconds 
delay in our proposed approach was selected based on our previous study [136] which 
showed that other delay periods (10s, 1min, and 2mins) yield equivalent or less benefit 
in our experiment setup. However, the range we studied was limited and further testing 
on other delay period selections are still needed to fully characterize the potential of the 
pulse timing approach. Similarly, in our study the pulses were divided into three trains, 
but other or better possibilities may exist. It may also be helpful to develop a model to 
characterize the effect of pulse timing. To achieve that, a better understanding of the 
pore recovery time frame and IRE injury mechanism is highly needed.  
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Appendix A1. Comparison of Irreversible Electroporation, Cryo, and Thermal Ablations 
on Cardiovascular Cells 
 
Contributing Authors: Chunlan Jiang, Jeunghwan Choi, Dushyant Mehra, Pong Patana-
anake, and John C. Bischof 
 
The following chapter appeared in publications:  
C. Jiang, J. Choi, D. Mehra, P. Patana, and J. C. Bischof, “Comparison of Irreversible 
Electroporation, Cryo, and Thermal Ablations on Cardiovascular Cells”, presented at the 
ASME Design of Medical Device Conference, April, 2014. 
 
A1.1 Introduction 
Cardiovascular disease remains the number one cause of death in the United States, 
and was responsible for approximately 6 million deaths of men and women in 2011 [163] 
Many acquired cardiovascular diseases are associated with abnormal proliferation of 
vascular smooth muscle cells (e.g. heart attack) or irregular electrical pathways (e.g. 
arrhythmia). Of the various methods applied to manage cardiovascular diseases, using 
energy-based technologies to create myocardial lesions (i.e. “ablation”) has gained 
increasing popularity due to their effectiveness, short treatment times, and minimal 
surgical damages.      
  
Thermal energy was one of the earliest technologies used for catheter ablation and 
currently has the greatest patient-year experience [155]. Various modalities, such as 
radiofrequency, high-intensity focused ultrasound (HIFU), catheter-based cryoablation, 
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focused laser, and microwaves, have been proposed as potential sources for 
cardiovascular ablation.  
  
Irreversible Electroporation (IRE), an emerging focal ablation modality that has attracted 
much interest in cancer research, may also provide new opportunities for treatments of 
cardiovascular diseases. Unlike thermal technologies, IRE is based on the electrical field 
distribution rather than diffusion, and induces cell death by increasing permeability, thus 
leaving long-term defects within cell membranes [1]. Although there have been several 
studies on IRE ablation of cardiovascular cells [164] and tissues (i.e. artery [107] and 
myocardial [110]), direct comparison between IRE and thermal ablation has yet to be 
done on the same biological model. 
  
In this report, we evaluated the ability of IRE to destroy cardiovascular cells and 
compared the results with those of cryo and thermal ablations on the same model. To do 
so, we use an atrial cardiac muscle cell line (HL-1 [156]) in order to characterize the 
biophysical effects and efficacy of these therapies. Specific influences of applied 
therapeutic variables for each modality (IRE: electric field (E-field), pulse duration and 
number, cryo and thermal: cooling/heating rate, end temperature and holding time) were 
studied and compared based on a common measure of injury (i.e., cell membrane 
integrity). The results presented here will likely aid in the selection of the best singular or 
combinatorial approach to treat cardiovascular diseases among the three studied 
modalities. 
 
A1.2 Materials and Methods 
A1.2.1 Cardiac muscle cell cultures 
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A HL-1 cell line was cultured as adherent monolayers [156]. More specifically, cells were 
grown in T-75 flasks with Claycomb medium (51800C, Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum, 2mM L-Glutamine, 100U/ml of 
Penicillin/Streptomycin, and 0.1mM Norepinephrine. When 90% confluence was reached 
and spontaneous beating was elicited (observed under the microscope), the cells were 
detached by adding 0.05% Trypsin-EDTA (Invitrogen, CA) and then formed into a single 
cell suspension (0.5~0.6 million cells/ml). 
 
A1.2.2 Irreversible Electroporation Treatment 
400μl volumes of the prepared HL-1 suspensions were pipetted into electroporation 
cuvettes (Fisher Scientific), which were then placed in an external electrical field created 
by an electrical pulse generator (BTX ECM 830, Harvard Apparatus). The output 
voltages and currents were monitored by an oscilloscope (Tektronix TDS 2002).  
  
A1.2.3 Cryoablation Treatment 
10μl volumes of the prepared HL-1 suspensions were pipetted into a crucible which was 
placed on a controlled temperature stage in conjunction with a light microscope to 
observe freezing of the samples. Before cooling, samples were pre-nucleated by 
applying a chilled needle on the outer edge of the sample. The end temperature (-5 to -
60 oC), and hold time (0 to 5 min) were varied among experiment groups, while cooling 
rate was kept constant at 5oC/min. This constant cooling rate was chosen best on 
preliminary results (data not shown) that suggest peak survival at this rate compared to 
faster or slower rates. 
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A1.2.4 Thermal (Heat) Treatment 
10μl volumes of the prepared HL-1 suspensions were placed in a sample pan then 
placed in a differential scanning calorimeter which controls the heating rate and end 
temperature. The cells were first held at 25oC for 1 min before being heated to end 
temperatures between 40 to 70oC at 5oC/min, then immediately cooled to 25oC at 
130oC/min. After heating, the cells were kept at 37oC for 3 hours before injury evaluation. 
  
A1.2.5 Injury Evaluations  
After treatments, aliquots of the treated cell suspensions were incubated with Hoechst 
33342 (10μM) and Propidium iodide (PI) dyes (7.5μM) for 15mins. These samples were 
then observed under a fluorescent microscope and photos were taken to calculate 
relative cell viability. 
 
A1.3 Results 
All treatment methods in our experiment were able to achieve complete (more than 95%) 
cell destruction with appropriate combination of therapeutic parameters. Specifically, for 
IRE the electric field required for complete cell destruction is 1250V/cm with 99 of 50μs 
long pulses. Pulse number has significant impact on E-field threshold. With 50 pulses, 
the E-field threshold increased to 1500V/cm. With 10 pulses, we were unable to achieve 
viability lower than 20% with even the highest E-field. For cryo, with a cooling rate of 
5oC/min, the end temperature required for complete cell destruction is lower than -40oC. 
Changing holding time from 1 to 5 minutes appears not to be a deterministic factor for 
cell viability in this cell line. For heating at 5oC/min and no holding time at the end 
temperature, the injury started to occur when end temperature went over 45oC. 
However, complete cell destruction was not achieved until end temperature reached 
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60oC. The heating injury kinetics has been characterized with more details from previous 
studies in our lab [165]. 
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Figure A1.1. Viability results of the HL-1 cell line after treatments of (a) IRE with E-field of 
50~500V, 50μs pulse duration and 10~99 number of pulses, (b) Cryoablation with end 
temperatures of 0~-60oC, 5oC/min cooling rate and 0~5min holding times, (c) Heating with end 
temperatures of 40~70oC, 5oC/min heating rate and no holding times. (N=4, error bars represent 
standard deviations) 
 
Our experiment results indicate that IRE is capable of destroying cardiovascular cells as 
well as cryo and heat ablations.  The critical therapeutic factors for IRE are E-field, pulse 
duration and numbers, verses end temperature, cooling rate for cryo or holding time for 
heating. Over 98% cell destruction was achieved with 99 of 50μs IRE pulses over 
1250V/cm. However, the time required for IRE to deliver treatment is significantly shorter 
than that of cryo and heating (Table A1.1). Although all three modalities suffer from a 
“transition zone” from initial to complete injury, it is likely that in vivo it is more important 
an issue for heating and cryo since there will be diffusional limitations that would slow 
heat and cold down. However, further modeling and experimental characterization are 
necessarily to confirm these arguments. 
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Table A1.1. Treatment comparison 
 
IRE Cryo Heat 
Duration <10s >10min >10min 
Critical 
Factors 
Electric field,  
pulse duration,  
pulse number 
End temperature, 
Cooling rate 
End temperature, 
holding time 
Initial Injury 
Threshold 
750V/cm,  
100 of 50us pulses 
-10
o
C at 5
o
C/min 40
o
C for 0 min 
Complete 
Injury 
Threshold 
1250V/cm,  
100 of 50us pulses 
-40
o
C at 5
o
C/min 60
o
C for 0 min 
Issues Muscle contraction 
Heat diffusion from 
blood vessels 
Heat diffusion from 
blood vessels 
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Appendix A2. Possibility of Protein Denaturation during Irreversible Electroporation 
 
A2.1 Introduction 
One of the major benefits claimed for IRE compared to other traditional focal therapies 
(radiofrequency heating or cryosurgery) is that IRE does not rely on thermal effect to 
create injury. Many theoretical and experimental studies [52], [101], [111] have 
confirmed that although tissue heating does exist during IRE due to Joule heating, the 
temperature rise and thermal dose are too low to induce significant thermal injury. 
Therefore, other mechanisms primarily associated with lipid membrane poration or 
permeabilization are thought to be responsible for cell injury during IRE as reviewed in 
previous chapters (Chapter 1.3.3, Chapter 3, Chapter 5.1). While these mechanisms are 
generally accepted, there is also the possibility that IRE could cause protein 
denaturation and that too can contribute to cell injury. This appendix shows some 
preliminary results that begin to address whether IRE has an impact of cellular proteins. 
  
A2.2 Materials and Methods 
A2.2.1 Cardiac muscle cell cultures 
A HL-1 cell line was cultured as adherent monolayers [156]. More specifically, cells were 
grown in T-75 flasks with Claycomb medium (51800C, Sigma-Aldrich, St. Louis, MO) 
supplemented with 10% fetal bovine serum, 2mM L-Glutamine, 100U/ml of 
Penicillin/Streptomycin, and 0.1mM Norepinephrine. When 90% confluence was reached 
and spontaneous beating was elicited (observed under the microscope), the cells were 
detached by adding 0.05% Trypsin-EDTA (Invitrogen, CA) and then formed into a single 
cell suspension (0.5~0.6 million cells/ml).  
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A2.2.2 Irreversible Electroporation Treatment 
400μl volumes of the prepared HL-1 suspensions were pipetted into electroporation 
cuvettes (Fisher Scientific), which were then placed in an external electrical field created 
by an electrical pulse generator (BTX ECM 830, Harvard Apparatus). The IRE 
parameters were chosen to be 300V, 50µs, 50#, and 10Hz. The output voltages and 
currents were monitored by an oscilloscope (Tektronix TDS 2002).  
   
A2.2.4 Thermal (Heat) Treatment 
10μl volumes of the prepared HL-1 cells were placed in a sample pan then placed in a 
differential scanning calorimeter (DSC) which controls the heating rate and end 
temperature. The cells were first held at 25oC for 1 min before being heated to end 
temperature of 85oC at 5oC/min, after being held at 85oC for 1 min, the cells were cooled 
to 25oC at 5oC/min and then the first step was repeated.  These protocols have been 
previously established to insure a controlled and uniform denaturation of the cellular 
proteins in a cell type of interest [165].  The difference between the excess specific heat 
in the initial and final heating protocol is a measure of available protein denaturation 
within that cell system. Anything that reduces the protein available for denaturation in the 
first step will reduce the overall excess specific heat due to protein denaturation. This in 
turn can then be further interrogated as a source of protein denaturation prior to heating 
(i.e. potentially IRE). 
  
A2.2.5 Protein Denaturation Assay  
The IRE treated cell suspension was centrifuged and transferred to the DSC machine for 
protein denaturation assay as described in [165]. The protein denaturation is measured 
by comparing the apparent specific heats between the initial and final heating cycles. 
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The cell concentrations of both the IRE and heat treated cells are standardized so that 
the initial protein concentration per cell population was the same and hence a change in 
the excess specific heat would imply the amount of protein that was available to 
denature in the two cases (IRE VS. heat alone). 
 
A2.2.6 Data Analysis 
The second heating curve in each Cp graph was corrected using a baseline correction 
protocol [165]. The difference in the area under the first heating and second heating 
corrected was obtained from each graph and averaged in order to create the total 
denaturation plots. The IRE, post heating, and control curves were normalized using the 
corresponding control curve for that set of experiments. The average of the 
normalizations was used in order to obtain the fractional denaturation plots.  
 
A2.3 Results and Discussion 
Both the IRE and heating protocols were chosen at levels that would induce 100% cell 
destruction (Figure 1.6, [165]). As can be seen from Figure A2.1, almost 100% protein 
has denatured post heating treatment. This result is expected since protein denaturation 
is a major mechanism of heat injury. However, despite the fact that IRE does not cause 
injurious heating at our chosen level, only a fraction (~33%) of the protein was left 
undenatured after IRE.  
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Figure A2.1. Fraction of protein denaturation post IRE and heating. (N=10 error bars represent 
standard errors) 
 
At least two possible mechanisms can explain why the amount of protein that denatured 
was significantly lowered after IRE. Firstly, although our chosen IRE level does not 
cause heat induced protein denaturation, it is possible that some proteins in the cells 
were electrically denatured due to intensive electric shock. This mechanism was first 
proposed by Lee. et. al. [34] and was named “electro-conformational denaturation” of 
proteins, many of which are related to the iron channels or pumps on the cell membrane. 
In addition, because of the permeability change during and shortly after IRE, intercellular 
proteins could leak out of the cell membrane and be washed out with the medium during 
centrifugation. Further study is still needed to characterize what portion of the protein 
loss was due to denaturation versus membrane leakage. Nevertheless, these initial 
123 
results clearly indicate that protein loss by denaturation or leakage is likely a real and 
underappreciated event that may contribute to injury during IRE. 
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Appendix A3. Electroporation with Low Electric Fields and Extra Large Pulse Numbers 
 
A3.1 Introduction 
The role of the three critical IRE parameters has been discussed previously in Chapter 
1.3.4. In brief, the electric field appears to be the deterministic factor of injury post IRE. 
For the LNCaP cell line, when the electric field is lower than 500V/cm, simply increasing 
the pulse number or pulse duration cannot induce cell injury from IRE (Figure 1.5). 
Moreover, the pulse number and pulse duration appears to act as treatment dosage of 
IRE. When the electric field exceeds a specific threshold, the number and duration of the 
pulses can affect how much percentage of cells can be killed.  
 
However, this appears to be contradictory to the findings from a study by Rubinsky’s 
group [17], in which complete cell death (100%) can be achieved for an E-field as low as 
125V/cm. As this result is in direct conflict with most of the field [Weaver], we set out to 
repeat the study and test if complete cell death can be achieved by low E-field (lower 
than 500V/cm) given sufficient pulse number and duration. 
  
A3.2 Materials and Methods 
The cell line we used for this study is LNCaP Pro 5, a prostate cancer cell line we have 
used in Chapter 2. The cell culture procedure, IRE protocol, and viability assessment 
methods are exactly the same as described in Chapter 2.  
 
 
A3.3 Results and Discussions 
Our results (titled UM results) are summarized and compared with Rubinsky’s [17] in 
Table A3.1. The pulse duration and frequency are the same in both studies. Only pulse 
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number and electric field and cell type have been changed for each data point. Both of 
our results achieved around 54% viability after IRE for 17 of 1500V/cm IRE pulses. 
However, the results start to diverge for cases with 1000V/cm and 750V/cm. The biggest 
difference happens with electric fields lower than 500V/cm. In our results, increasing the 
pulse number to extreme large numbers (e.g. 3840 at 125V/cm) did not induce 
significant cell destruction (<10%), while in Rubinsky’s results, complete cell destruction 
(100%) was achieved for the same parameter combo.  
 
             
Table A3.1. Comparison of viability results after IRE treatment in vitro. (pulse duration is 100µs, 
frequency is 10Hz for all cases) 
Pulse # 3840 960 240 106 60 17 
E-field 125 250 500 750 1000 1500 
UM results 
(n=3, ave±SD%) 93±0.2 88±2 90±2 46±8 43±8 54±14 
Rubinsky's results  
(n=12, ave±SD%) 0 0 0 12±4 27±9 56±12 
 
Although variations of some experimental conditions could cause differences in the 
viability results, such as cell type, medium component, and viability assay, the huge 
differences between our studies (10% versus 100% cell destruction) is hard to be 
accounted for with these variations. 
 
Another factor that might cause significantly higher cell destruction in Rubisky’s study is 
the possibility of introducing delays between pulse trains when applying the large pulse 
numbers (240~3840). The pulse number that can be delivered in one train with their 
pulse generator (ECM 830, Harvard Apparatus) is 99. To deliver up to 3840 pulses in 
one treatment, at least 39 pulse trains need to be applied. If the researcher introduced 
seconds of delays between these pulse trains, the injury can be significantly enhanced 
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due to the pulse timing enhancement effect introduced in Chapter 2 and 3. In summary, 
our attempts to repeat the findings in Rubinsky’s study [17] that complete cell destruction 
can be achieved with ultra-low electric fields (<500V/cm) and large pulse numbers was 
not successful. This suggests, based on our results and the literature we have reviewed 
in Chapter 1, that E-fields of >500V/cm are needed for IRE. 
 
 
